Nonspherical Nanoparticle Shape Stability Is Affected by Complex Manufacturing Aspects: Its Implications for Drug Delivery and Targeting by Haryadi, Bernard Manuel et al.
www.advhealthmat.de
PROGRESS REPORT
1900352 (1 of 31) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Nonspherical Nanoparticle Shape Stability Is Affected  
by Complex Manufacturing Aspects: Its Implications  
for Drug Delivery and Targeting
Bernard Manuel Haryadi,* Daniel Hafner, Ihsan Amin, Rene Schubel, Rainer Jordan, 
Gerhard Winter, and Julia Engert
DOI: 10.1002/adhm.201900352
1. Introduction
For a long time, biodegradable nanoparticle drug delivery sys-
tems have been investigated for numerous applications such 
as cancer treatment, vaccination, and iron replacement.[1,2] 
Nanoparticles may extend the half-life of delivered drug,[3,4] 
avoid drug degradation,[5] and modulate uptake into antigen-
presenting[6,7] or other target cells.[8–10] The bio-physicochem-
ical characteristics of drug delivery systems, viz. size, charge, 
surface behavior and composition of the polymer are conven-
tionally considered, as these key factors impact on particle 
biodistribution. Although all aforementioned characteristics 
have been optimized to circumvent the rapid clearance by the 
mononuclear phagocyte system (MPS) in the spleen and liver,[3] 
in vivo results frequently fail to meet the expectation.[3] Thus, 
there is a need to refine this flaw, for instance by means of the 
geometry aspect.
Classically, particle shape has been disregarded as a fea-
ture, which may switch the biodistribution and circulation 
half-life. Sundry manufacturing methods, such as mechanical 
stretching,[6,11–13] lithography,[14–16] nonwetting templates,[17] 
The shape of nanoparticles is known recently as an important design parameter influencing considerably the fate of 
nanoparticles with and in biological systems. Several manufacturing techniques to generate nonspherical nanoparticles 
as well as studies on in vitro and in vivo effects thereof have been described. However, nonspherical nanoparticle shape 
stability in physiological-related conditions and the impact of formulation parameters on nonspherical nanoparticle 
resistance still need to be investigated. To address these issues, different nanoparticle fabrication methods using 
biodegradable polymers are explored to produce nonspherical nanoparticles via the prevailing film-stretching method. 
In addition, systematic comparisons to other nanoparticle systems prepared by different manufacturing techniques 
and less biodegradable materials (but still commonly utilized for drug delivery and targeting) are conducted. The study 
evinces that the strong interplay from multiple nanoparticle properties (i.e., internal structure, Young’s modulus, surface 
roughness, liquefaction temperature [glass transition (Tg) or melting (Tm)], porosity, and surface hydrophobicity) is pre-
sent. It is not possible to predict the nonsphericity longevity by merely one or two factor(s). The most influential features 
in preserving the nonsphericity of nanoparticles are existence of internal structure and low surface hydrophobicity (i.e., 
surface-free energy (SFE) > ≈55 mN m−1, material–water interfacial tension <6 mN m−1), especially if the nanoparticles 
are soft (<1 GPa), rough (Rrms > 10 nm), porous (>1 m2 g−1), and in possession of low bulk liquefaction temperature 
(<100 °C). Interestingly, low surface hydrophobicity of nanoparticles can be obtained indirectly by the significant pres-
ence of residual stabilizers. Therefore, it is strongly suggested that nonsphericity of particle systems is highly dependent 
on surface chemistry but cannot be appraised separately from other factors. These results and reviews allot valuable 
guidelines for the design and manufacturing of nonspherical nanoparticles having adequate shape stability, thereby 
appropriate with their usage purposes. Furthermore, they can assist in understanding and explaining the possible 
mechanisms of nonspherical nanoparticles effectivity loss and distinctive material behavior at the nanoscale.
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and microfluidics,[18] enable the preparation of nonspherical 
nanoparticles and entitle the further investigation of particle 
geometry’s influence on biological half-life and fate. It has been 
demonstrated that (prolate) ellipsoid particles display a lower 
internalization by macrophages.[8,19,20] In contrast, other geom-
etries like discs (oblate ellipsoid) induce phagocytosis.[21] Ellip-
soid particles also permit better antigen delivery to T cells.[9,22] 
These findings indicate that particle shape can be an eminent 
element affecting the fate of particulate drug delivery systems. 
However, the stability of nanoparticle shapes is still not much 
studied for biodegradable–biocompatible particles.
Therefore, the aim of this study is to comprehensively 
examine the correlation between nonspherical biodegrad-
able nanoparticle shape stability and the physicochemical 
properties factors behind it, in physiological-related condition 
(37 °C, phosphate buffer saline (PBS) pH 7.4 310 mOsm). 
The film-stretching method was employed under dry heat to 
produce nonspherical nanoparticles from the spherical ones. 
The spherical nanoparticles were prepared by diverse fab-
rication methods (a. cross-linking: physical & chemical; b. 
molecular entanglement: emulsion solvent extraction & nano-
precipitation) and biodegradable materials (O-carboxyme-
thyl chitosan [O-CMCHS], gelatin, carboxyl-ended poly(d,l-
lactic acid) [PLA-COOH], and poly(d,l-lactic-co-glycolic acid) 
[PLGA-COOH]). In addition, we benchmarked the results 
to the common model, but less biodegradable nanoparti-
cles (carboxylated poly(styrene) [PS-COOH] and silica [SiO2] 
nanoparticles). In principle, several determining factors 
related to the nanoparticle shape stability have been eluci-
dated and suggest that they strongly affect each other. In fact, 
the significant extent of residual stabilizers, which existed 
on nanoparticles, exhibited the best stability in terms of 
nonsphericity. We also discuss thoroughly this underlying issue 
and its potential implications for drug delivery and targeting.
2. Results
All spherical nanoparticles as a base of nonspherical nanoparti-
cles were prepared in the similar hydrodynamic size (Table 1). 
Subsequently, the stretching in one direction with a stretching 
factor of 3 was performed toward spherical samples embedded 
in a poly(vinyl alcohol) (PVA) (Mowiol 40–88; bulk Tg ≈ 85 °C[23]) 
film using a custom built device (Figure 1a) at certain stretching 
condition for different materials (Table S1, Supporting Informa-
tion; see also Methods in Supporting Information for further 
details of particles embedment in the PVA film). The character-
istics of resulted nonspherical (quasi prolate/elongated) nano-
particles after the standardized washing steps (see Methods in 
Supporting Information) are depicted in Table 1 and Figure 1b,c. 
The increase of hydrodynamic size and polydispersity index 
(PDI) was clearly observed on nonspherical nanoparticles, 
whereas zeta potential exhibited practically no change.
2.1. Effect of Fabrication Method
First, the comparison between two fabrication methods (cross-
linking vs molecular entanglement) was performed. Because 
of the stabilizer/surfactant absence in the cross-linking 
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method, nanoprecipitation (no stabilizer/surfactant; also 
called solvent displacement[24,25] elsewhere) is the main focus 
in molecular entanglement development instead of methods 
involving stabilizer (e.g., emulsion solvent extraction; also 
called [emulsion] solvent diffusion[24,26] or [emulsion] solvent 
evaporation[2,24]) (Table 1).
The size of cross-linked hydrogel nanoparticles demon-
strated by scanning electron micrographs (SEM) (Figure 1b) 
was measured in dry milieu (leading to significant particle 
shrinking), thus may be considerably different as reported by 
dynamic light scattering (DLS) in Table 1.[27] No significant 
shrinking of nanoparticles occurred on more solid nanoparti-
cles composed from aliphatic polyesters via nanoprecipitation 
and commercial standard PS-COOH (Figure 1c). After three-
times stretching from its initial length, both cross-linked 
hydrogel nanoparticles appeared to be slightly elongated with 
initial aspect ratio (defined as the proportion of length to 
width ellipsoid particle) of 1.62 ± 0.18 and 1.11 ± 0.09 for gel-
atin and O-CMCHS, consecutively. These aspect ratios were 
much lower compared to the theoretical calculation (Figure 1d 
and Supplemental Calculation, Supporting Information). In 
addition, considerable swelling was exhibited by both, mainly 
gelatin nanoparticles (Figure 1b).
Over time, an obvious discrepancy was noted between the 
shape stability of the nonspherical nanoparticles. These dis-
crepancies were not equal for all particles, but were strongly 
affected by many factors, including the fabrication method. To 
allow better shape stability prediction and comparison between 
the tested samples, the typical shifting time (t1/2) (expressed as 
the time needed for a half decrease of initial aspect ratio) was 
calculated. In hours, both nonspherical cross-linked hydrogel 
particles became virtually spherical at 37 °C (aspect ratio = 1; 
figures not shown), with gelatin demonstrated slightly better 
shape stability (Figure 1e). Due to swelling and poor shape 
stability, gelatin and O-CMCHs are only used as references 
in elucidating the factors affecting shape transformation of 
nonspherical nanoparticles.
Meanwhile, nonspherical nanoparticles formulated by ali-
phatic polyesters (Table S2, Supporting Information) and 
nanoprecipitation method exhibited much higher t1/2 at 37 °C 
(Figures 1e, 2, and 3a [left], b,c), with PLGA 50/50-COOH 
(≈44 kDa) being the inferior one with almost 6 d. Because 
of this, our further study with emulsion solvent extraction 
method (involving stabilizer) for aliphatic polyesters is only 
focused on PLA-COOH and PLGA 75/25-COOH. Besides, 
the recent indication to use low molecular weight of ali-
phatic polyesters (≈15 kDa) for drug delivery[28] due to the 
success in clinical study, reinforces our polymer choices. As 
expected, the t1/2 of PLGA 75/25-COOH & PLA-COOH nan-
oparticles by nanoprecipitation were much greater at 5 °C 
(Figures 1e, 2b, and 3b).
Nonetheless, the shape stabilities of nonspherical PLGA 
75/25-COOH and PLA-COOH nanoparticles formulated by 
nanoprecipitation were still much poorer than the commer-
cial standard PS-COOH prepared by emulsion polymerization 
(Figures 1e, 2, and 3b), i.e., approximately less than one-sixth at 
37 °C and less than half at 5 °C. By applying emulsion polymer-
ization in commercial standard PS-COOH, stabilizer was used 
during the preparation process and residual stabilizers may pre-
sent in nanoparticles (Polysciences’ Product Information).[29] To 
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Table 1. Characteristics of spherical and nonspherical nanoparticles used in the study (Data are expressed as mean ± standard deviation (n = 3)).
No. Polymer Preparation 
method
Involvement of 
stabilizer
Hydrodynamic size,  
Sh [nm]
Polydispersity  
index PDI
Zeta potential  
[mV]
Yield  
[%]
Spherical Nonspherical Spherical Nonspherical Spherical Nonspherical
1 PLA-COOH Nanoprecipitation No 179.3 ± 4.1 404.5 ± 17.8 0.055 ± 0.043 0.215 ± 0.096 −14.2 ± 0.6 −15.5 ± 1.7 96.2 ± 3.2
Emulsion solvent 
extraction
Yes (PVA)
Yes (P407)
Yes (TPGS)
175.1 ± 3.3
180.8 ± 0.6
153.5 ± 2.6
413.7 ± 20.4
419.3 ± 9.9
410.0 ± 14.1
0.043 ± 0.033
0.055 ± 0.023
0.134 ± 0.029
0.213 ± 0.028
0.254 ± 0.027
0.194 ± 0.019
−7.6 ± 1.4
−9.6 ± 2.3
−11.5 ± 0.9
−8.2 ± 2.3
−8.4 ± 1.5
−10.9 ± 1.2
80.6 ± 2.1
75.5 ± 2.3
72.1 ± 2.0
2 PLGA 
75/25-COOH
Nanoprecipitation No 172.3 ± 3.8 390.6 ± 6.9 0.081 ± 0.010 0.273 ± 0.023 −13.4 ± 2.3 −14.1 ± 0.5 95.7 ± 3.9
Emulsion solvent 
extraction
Yes (PVA) 168.1 ± 0.8 430.3 ± 13.4 0.029 ± 0.028 0.223 ± 0.025 −8.5 ± 1.7 −7.6 ± 0.6 81.1 ± 0.8
3 PLGA 
50/50-COOH
Nanoprecipitation No 176.6 ± 0.9 346.8 ± 6.6 0.022 ± 0.015 0.157 ± 0.063 −12.6 ± 1.2 −11.5 ± 1.0 63.8 ± 1.5
4 O-CMCHS Ionic gelation No 167.6 ± 0.8 382.6 ± 7.3 0.168 ± 0.007 0.145 ± 0.047 −11.4 ± 0.6 −3.7 ± -0.3 35.2 ± 0.2
5 Gelatin One-step 
desolvation
No 188.1 ± 1.5 1007.0 ± 173.9 0.053 ± 0.009 0.632 ± 0.234 −16.6 ± 1.0 −2.0 ± 0.3 81.4 ± 0.3
6 PS-COOH Emulsion 
polymerization
Yes (sulfate 
ester 
derivative)
178.8 ± 3.0 341.4 ± 9.7 0.032 ± 0.022 0.191 ± 0.031 −30.3 ± 0.8 −17.2 ± 0.3 N/Aa)
7 SiO2 (AR3) Polymerization Yes (CTAB) N/Aa) 255.5 ± 5.3 N/Aa) 0.228 ± 0.023 N/Aa) −26.3 ± 1.5 88.3 ± 0.4b)
8 SiO2 (AR8) Polymerization Yes (CTAB) N/Aa) 929.0 ± 16.2 N/Aa) 0.478 ± 0.023 N/Aa) −22.9 ± 1.7 89.7 ± 0.2b)
a)N/A, not applicable; b)Only these yields represent the direct (without film-stretching) processes in fabricating nonspherical nanoparticles. Other yields are based on the 
production of the spherical nanoparticles.
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Figure 1. a) Schematic of film-stretching device utilized in this study for fabrication of nonspherical nanoparticles from spherical ones. It is also dis-
played the common and plausible architecture alteration of polymers at the nanoparticle interface after stretching,[187] involving the transition from 
“mushroom” to “brush” configuration. Scanning electron micrographs of spherical and nonspherical b) cross-linked hydrogel nanoparticles, encom-
passing O-CMCHS and gelatin, as well as c) aliphatic polyesters (prepared by nanoprecipitation) and PS-COOH nanoparticles (scale bars = 500 nm). 
For clarity, spherical nanoparticles of aliphatic polyesters and PS-COOH before their incorporation into film are not shown. d) Critical physical factors 
on prolate ellipsoid particle influenced by uniaxial stretching process. e) Calculation of typical shifting time (t1/2) from aspect ratio (AR) of particles. 
f) Physiosorption-based surface characteristics of various evaluated nanoparticles. g) Mechanical properties of tested nanoparticles. Unless otherwise 
specified in Methods in Supporting Information, data represents mean ± standard deviation (n = 3).
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Figure 2. Representative scanning electron micrographs obtained on different days after initial preparation displaying shape stability of nonspherical 
aliphatic polyesters (PLA-COOH & PLGA 75/25-COOH) and PS-COOH nanoparticles. Nanoparticles were dispersed in phosphate buffer saline (PBS) 
pH 7.4 310 mOsm for a maximum of 29 d at a) 37 °C and b) 5 °C. Scale bars = 500 nm.
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also permit stabilizer contribution in aliphatic polyester nano-
particles, an emulsion solvent extraction method with different 
stabilizers was employed. PVA (Mowiol 4–88), a semicrystalline 
polymer, elicited dramatic improvement of nonspherical shape 
stability for PLA-COOH and PLGA 75/25-COOH, both at 37 
and 5 °C (Figures 1e, 2, and 3b). At 37 °C, the t1/2 was enhanced 
up to about 11 times for PLA-COOH and fivefolds for PLGA 
75/25-COOH. Other stabilizers a) Poloxamer 407 (P407) and b) 
D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) were 
also evaluated in the fabrication of nonspherical PLA-COOH by 
emulsion solvent extraction. However, they failed to increase the 
non-spherical shape stability of PLA-COOH (Figure 3a,c). No 
considerable t1/2 alteration was observed between nanoparticles 
manufactured by emulsion solvent extraction using these stabi-
lizers compared to the nanoprecipitation at 37 °C, i.e., between 
6 and 8 d (Figure 3a,c). In this part, it can be summarized that 
for biodegradable polymers, PLGA 75/25-COOH prepared by 
emulsion solvent extraction using PVA is the longest-lasting ali-
phatic polyester in terms of nonsphericity. It is characterized by 
t1/2 at 5 °C for almost 1 year and at 37 °C for roughly 3 months 
(Figure 1e). For this reason, PVA is chosen as the main discus-
sion and stabilizer evaluated further in this report.
Adv. Healthcare Mater. 2019, 8, 1900352
Figure 3. a) Scanning electron micrographs obtained on different days after initial preparation displaying shape stability of PLGA 50/50-COOH nano-
particles (formulated by nanoprecipitation) and PLA-COOH nanoparticles (manufactured by emulsion solvent extraction (ESE) technique with the 
variation of utilized stabilizers; in this figure, Poloxamer 407 denoted “P407” and TPGS are evaluated instead of PVA used in Figure 2). Scale bars = 
500 nm. b,c) Plots of aspect ratio (AR) over time of aliphatic polyester prepared by different fabrication methods and PS-COOH nanoparticles at 5 °C 
and 37 °C. Figure 3b corresponds to the micrograph results from Figure 2a,b, meanwhile Figure 3c was derived from the measurement results of 
Figure 3a. Aspect ratio (AR) is calculated as described in the top of Figure 3b.
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Beside aspect ratio reduction, the inclinations to be spherical 
ultimately at 37 °C for nonspherical nanoparticles synthesized 
by film-stretching method were also supported by the results of 
hydrodynamic size measurement and PDI by DLS (Figure 4). 
DLS detected a gradual decrease of both parameters. There was no 
significant change of zeta potential and pH for all nanoparticles 
Adv. Healthcare Mater. 2019, 8, 1900352
Figure 4. Plots of hydrodynamic size, polydispersity index/PDI, zeta potential, and final preparation pH of low molecular weight aliphatic polyesters 
(PLA-COOH & PLGA 75/25-COOH) and PS-COOH nanoparticles over time. Aliphatic polyesters were prepared by different fabrication methods: emul-
sion solvent extraction (ESE) using PVA and nanoprecipitation. The data and time points in this figure correspond to Figures 2 and 3b.
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stored at 5 °C, but substantial alteration of zeta potential and 
pH toward more acidic environment was observed at 37 °C on 
both aliphatic polyester nanoparticles (Figure 4). Meanwhile, 
PS-COOH nanoparticles exhibited practically no change of zeta 
potential and pH during observation (Figure 4).
To elaborate the causal factor of nonspherical shape insta-
bility on nanoparticles, the other factors (mechanical properties, 
porosity and hydrophobicity) are studied on selected nanoparti-
cles and their data is displayed in the next sections.
2.2. Effect of Mechanical Properties: Young’s Modulus,  
Surface Roughness (Rrms), and Tg
All nanoparticles were initially analyzed for mechanical proper-
ties in dry condition. Using atomic force microscope (AFM), it 
was revealed that they had relatively smooth surfaces, demon-
strated by Rrms (Figures 1f and 5a) about tens nm or less,[30,31] 
and proportional Young’s modulus to their bulk and the sim-
ilar particles reported elsewhere.[23,32–34] Spherical gelatin and 
spherical PLGA 50/50-COOH nanoparticles (via nanoprecipita-
tion) showed the smoothest and roughest surface (Rrms = 3.2 vs 
12.4 nm). As expected, cross-linked system is rather smooth.[35] 
Regarding the Young’s modulus, the softest and stiffest nano-
particles belong to gelatin (≈0.7 GPa) and PS-COOH (≈2 GPa) 
nanoparticles. Meanwhile, the Tg trends of (spherical) nanopar-
ticles were: a) slightly lower than the bulk for aliphatic polyes-
ters via nanoprecipitation and PS-COOH, and b) slightly higher 
than the bulk for aliphatic polyesters via emulsion solvent 
extraction and gelatin (Figure 1f).
After stretching, there were no considerable Young’s mod-
ulus, surface roughness, and Tg differences of dry nanoparti-
cles (prepared by lyophilization protocol; Figure S1, Supporting 
Information). The exception were: (a) gelatin nanoparticles 
obtaining greater Young’s modulus and surface roughness 
about twofolds and threefolds, respectively, as well as b) PS-
COOH and aliphatic polyesters, experiencing Tg reduction 
around 3 °C (Figure 1f). Nevertheless, there were clear trends 
that Young’s moduli of stretched (nonspherical) aliphatic poly-
esters were: a) slightly lower for nanoparticles prepared by nan-
oprecipitation (possibly due to Young’s modulus confinement 
effect[36]) and b) slightly higher for nanoparticles formed via 
emulsion solvent extraction utilizing PVA (Figure 1f). Besides, 
all stretched nanoparticles roughened after stretching, as 
depicted by greater Rrms (Figure 1f) and rougher sample surface 
profiles (Figure 5b vs a). The poststretching roughening effect 
is similar as commonly reported in micro-macroscale objects 
and various polymers.[37,38]
Surprisingly, it was revealed from the AFM results that 
between nanoparticles fabricated by nanoprecipitation, the 
spherical PLGA 50/50-COOH nanoparticles (the least-stable 
ones in terms of nonsphericity) have greater roughness (Rrms = 
12.4 nm) compared to PLGA 75/25-COOH (Rrms = 5.9 nm) and 
PLA-COOH (Rrms = 9.5 nm). This result could be correlated 
with the porosity and hydrophobicity measurement, which are 
displayed and discussed in the subsequent sections.
To further confirm the marginal trend of Tg modulation of dry 
nanoparticles (dry Tg) compared to their bulk, the Tg of nanopar-
ticles dispersed in aqueous medium (wet Tg) was also evaluated. 
Only polymers that could be successfully and proportionally 
stretched into nonspherical nanoparticles were studied, namely 
aliphatic polyesters and PS-COOH. None of aliphatic polyester 
nanoparticles (initial ø ≈ 200 nm), however, exhibited a wet Tgs. 
It was very probable that their wet Tgs were superimposed by 
large endothermic peak of aqueous ice melting process (data not 
shown). It was reported[39,40] that even in macroscopic scale, ali-
phatic polyesters exhibited Tg reduction up to ≈10–20 °C, when 
they were contacted with high humidity (e.g., 90%RH) or water 
for 1 h or more. The longer the contact time with humidity or 
water, the greater the Tg depreciation. On the other hand, PS-
COOH nanoparticles (initial ø ≈ 200 nm) showed more distinct 
Tg reduction, i.e., about 15 °C, compared to the dry ones (3 °C) 
(Figures 5c vs 1f). To study deeper the size dependence of Tg 
of polymers under soft confinement (nanoparticles dispersed 
in aqueous medium), other diameters of PS-COOH nanopar-
ticles (100 and 2000 nm) were measured. The wet Tg of the 
PS-COOH nanoparticles lessen as the hydrodynamic size was 
reduced from 2000 to 100 nm, and thus the disparity against 
their bulk Tg grew considerably with smaller hydrodynamic size 
(1 vs 39 °C, respectively) (Figures 5c vs 1f). Similar finding was 
reported elsewhere.[41] Moreover, heat capacity change (ΔCp) 
appeared to be lesser with smaller hydrodynamic size, which 
is consistent with the published results.[42,43] Both phenomena 
(the reduction of wet Tg and ΔCp) seemed to occur remarkably 
on non-spherical PS-COOH, obtained by 3x stretching of spher-
ical PS-COOH (initial ø ≈200 nm). This may be attributed to the 
smaller particle size (in width and height dimension) (Figure 5b 
vs a), existence of much lower radius of curvature (Rc(t)), and 
wide variance of Rc(t) on nanoparticles (Figure 1d). Likewise, the 
greater Tg diminution as smaller (hereafter denoted Tg confine-
ment effect) and more aspherical PS-COOH nanoparticles, it is 
also very reasonable to propose that the Tg confinement effect 
occurred in the case of other nanoparticle materials, including 
aliphatic polyesters. Not to mention, because all nanoparticles 
for shape stability study were dispersed in the physiologically 
relevant medium (PBS pH 7.4 310 mOsm), it was very likely 
that the stronger ΔCp reduction occurred. The salt presence was 
reported to diminish ΔCp of macromolecules significantly.[44] As 
a result, less energy (represented by temperature and interfacial 
tension) is required to increase the polymer chain mobility in 
nonspherical nanoparticles, thus leads to more dramatic shape 
changes towards spheres. The Tg confinement effect further 
delineates that lower temperature (i.e., 37 or 5 °C) may still 
induce the aspect ratio decrease on tested nonspherical nano-
particles, mainly aliphatic polyesters.
2.3. Effect of Porosity of Particles
To quantify the porosity and hydrophobicity of the nano-
particles, physiosorption-based methods (specific surface 
area (SSA) and residual moisture analysis) were performed 
(Figure 1g). The analyses were conducted on starting spherical 
nanoparticles to generate more reliable and directly comparable 
results due to no swelling and similar nanoparticle size. The 
SSA of biodegradable nanoparticles that were included in film-
stretching process highly varied, depending on the nanoparticle 
integrity, molecular weight, and bulkiness of the polymer chain.
Adv. Healthcare Mater. 2019, 8, 1900352
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For instance, with respect to nanoparticles prepared without 
any stabilizer or surfactant, PLGA 50/50-COOH and gelatin nan-
oparticles were the least compact, displayed by SSA of around 
3.05 and 1.57 m2 g−1, consecutively. For nanoparticles pre-
pared by nanoprecipitation, again PLGA 50/50-COOH (“high” 
molecular weight [MW], bulkier) was the most porous or least 
compact, whereas PLGA 75/25-COOH (“low” MW, less bulky) 
had the lowest porosity or highest compactness (0.55 m2 g−1).
Furthermore, stabilizer had a strong effect on SSA, such 
as in emulsion solvent extraction for aliphatic polyesters, 
resulting about twofold SSA compared to the nanoprecipa-
tion (Figure 1g). Overall, the nanoparticle material, having the 
highest porosity and produced to be nonspherical nanoparticles 
by stretching method, was PS-COOH (SSA ≈ 42 m2 g−1). We 
assume that the different amount of residual stabilizers may 
be one of the critical factors for the SSA differences between 
Adv. Healthcare Mater. 2019, 8, 1900352
Figure 5. Atomic force microscope (AFM)’s 3D representations and surface or height profiles of evaluated a) spherical and b) nonspherical nanoparticles. 
c) Calorimetric thermograms of PS-COOH nanoparticles (solid lines), altogether with thermograms of their corresponding “bulk” polymer resulted from 
nanoparticles via annealing (dashed lines). These thermograms describe the dramatic disparity of nanoparticle Tg measured on dispersed or dry state. 
d) Nanoparticle’s surface hydrophobicity (displayed by the slope of hydrophobicity and binding constant; the greater values mean greater hydrophobicity) 
and residual stabilizers (PVA) concentration profiles of tested nanoparticles. e) Correlation database of surface-free energy (SFE), material–water interfa-
cial tension, and water contact angle (WCA) of various common materials functionalized as main component or excipient (e.g., stabilizer) in nanoparticle 
formulations. The used materials in our current nonspherical nanoparticle study are designated as points (either dot or triangle) without black borderline 
(and their corresponding bars), whereas points with black borderline (and their corresponding bars) show common materials for nonspherical nanopar-
ticle fabrication used in other researches. The full points (and their corresponding bars) depict values generated from our measurement, while the half-
filled points (and their corresponding bars) designate the recalculation values of interfacial activity parameters (using Owens and Wendt approach[223]) 
from references. Yellow (and their corresponding bars) represents our and commonly used stabilizers, while red (and their corresponding bars) is denoted 
as commonly reported materials in synthesizing biodegradable and/or nonspherical nanoparticles for drug delivery and targeting. Abbreviations and 
further details of referred material–nanoparticles: (1) SDS (sodium dodecyl sulfate),[168,224] (2) Docusate-Na,[168] (3) Triton X-100,[124,225] (4) Na-Cholate 
& -Deoxycholate,[129,226] (5) PVP (poly(vinylpyrrolidone)),[137,227] (6) PEG (poly(ethylene glycol))[209] 6000,[228] (7) Dextran,[194,228] (8) Poloxamer 188,[127,229] 
(9) HSA (human serum albumin),[134,230] (10) Chitosan,[98,178] (11) Cyanoacrylate,[98,231] (12) PS-COOH (carboxylated poly(styrene)),[4,232] (13) PS (poly(sty
rene)),[19,223] (14) PDMS (poy(dimethylsiloxane)),[83,223] (15) PMMA (poly(methyl methacrylate)),[83,223] (16) PHEA (poly(hydroxyethyl acrylate)),[71,73,233,234] 
(17) PHEMA (poly(hydroxyethyl methacrylate)),[233] (18) PEGDA (poly(ethylene glycol) diacrylate)[14–16,71,73,79,86,235]-PHEMA (poly(hydroxyethyl meth-
acrylate)),[236] (19) CEA (2-carboxyethyl acrylate),[71,73,86] (20) PBLG (poly(γ-benzyl l-glutamate)),[142,237] (21) Triglyceride (cocoa butter),[115,116,160,163,164,238] 
(22) P4VP (poly(4-vinyl pyridine)),[149,150,239] (23) Au (gold),[220,240] and (24) SWCNT (single-walled carbon nanotubes).[46,241]
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these groups. Our assumption was supported by quite diverse 
SSA value reported for aliphatic polyesters by emulsion solvent 
extraction (3–10 m2 g−1)[45] and PS-COOH by emulsion polym-
erization (29 m2 g−1)[46] nanoparticles. These reports used sim-
ilar nanoparticle properties as reported here, namely diameter 
≈200 nm, PDI < 0.1, and negative zeta potential of tens mV (for 
aliphatic polyesters).
Meanwhile, the residual moisture results appeared as a 
function of porosity (Figure 1g) and bulk-nanoparticle hydro-
phobicity (Figure 5d,e). In general, the higher the residual 
moisture, the greater the SSA, and the lesser hydrophobic 
the materials or nanoparticles. In other words, the presence 
of residual stabilizers may increase the SSA and residual 
moisture. Nonetheless, a large SSA did not negatively correlate 
to nonspherical nanoparticle shape stability, if the sufficient 
mechanical properties and appropriate hydrophobicity (indi-
rectly encompassing residual stabilizers) were present.
2.4. Effect of Hydrophobicity of Materials and Particles
All nanoparticles (Figure 5d) were evaluated using the hydro-
phobic (log P 1.5[47]) anionic Rose Bengal dye method. Overall, 
the sequence of hydrophobicity between different nanoparticles 
(regardless of their shape) was as following (from the highest 
to the lowest): gelatin, PLA-COOH by nanoprecipitation, PLGA 
75/25-COOH by nanoprecipitation, PLA-COOH by emulsion 
solvent extraction, PS-COOH, and PLGA 75/25-COOH by 
emulsion solvent extraction. This strong trend was inversely 
proportional with the nonspherical nanoparticle shape stability 
at 37 °C (Figure 1e), but poorly correlated to the bulk hydro-
phobicity (Figure 5e). Hence, the particle hydrophobicity study 
showed its importance.
No significant difference was found between initial spherical 
and film-embedded (without stretching) spherical nanoparti-
cles in terms of nanoparticle hydrophobicity parameters, except 
for gelatin (Figure 5d). Unexpectedly, gelatin exhibited consid-
erable lower hydrophobicity, ascribed presumably by strong 
adsorption of PVA (Mowiol 40-88 as the film matrix) onto gel-
atin nanoparticles. This adsorption may be responsible for the 
tangled thread-like structure around filmed and film-stretched 
gelatin nanoparticles in SEM and AFM (Figures 1b and 5b). As 
the further proof of PVA (semicrystalline polymer) presence, 
the hydrophilicity (Figure 5d), Young’s modulus, and surface 
roughness (Figure 1f) of the nonspherical gelatin nanoparticles 
were greater compared to the initial spherical gelatin nanopar-
ticles. This may be attributed to the typical properties of semic-
rystalline polymer after stretching,[48] namely demonstration of 
higher crystallinity. However, we could not measure the exact 
concentration of adsorbed PVA onto gelatin nanoparticles like 
to the aliphatic polyesters, due to the interference of adjacent 
hydroxyl (Figure S2, Supporting Information) in gelatin against 
colorimetric reagents in the reaction.[49]
As expected, the significant hydrophobicity reduction of PLA-
COOH and PLGA 75/25-COOH nanoparticles fabricated by 
emulsion solvent extraction using PVA was strongly associated 
with its residue in nanoparticles, with the larger amount of PVA 
resided to PLA-COOH (the more hydrophobic polymer) com-
pared to PLGA 75/25-COOH, namely about 3% versus 1.5%, 
respectively (Figure 5d). Stronger PVA adsorption to the more 
hydrophobic materials aligns with established report.[50] None-
theless, our results demonstrated that the intrinsic material 
hydrophobicity still played a dominant role in determining the 
nanoparticle hydrophobicity and nonspherical shape stability.
With regard to PS-COOH, we presumed that the superiority 
of nonspherical shape stability may also be aided by the pres-
ence of residual stabilizers utilized in the nanoparticle forma-
tion, beside by the relatively high dry bulk Tg of PS-COOH 
(i.e., ≈93 °C, which is still slightly higher than gelatin, ≈91 °C) 
(Figure 1f) and bulk[32]-nanoparticle Young’s Modulus PS(-
COOH) ≈2 GPa. This proposition is highly reinforced with 
the slightly poorer hydrophobicity data of bulk PS-COOH 
compared to gelatin (Figure 5e). The unsupportive situation 
(Figure 5e) encompassed the much lower polar component 
of surface-free energy (SFE) (or so-called surface polarity, Xp), 
water contact angle (WCA), and most important one: high 
material–water interfacial tension. We propose that the high 
material–water interfacial tension is the main, external, and rig-
orous driven force generating the biggest pressure on the tip 
of nonspherical nanoparticles (in other words, on the smallest 
Rc(t) of nonspherical nanoparticles (Figure 1d) (Equation (1), 
adapted from Defay et al[51]). Consequently, the high interfacial 
tension leads to thermodynamically favorable spherical shape.
γ
( )∆ =
s.l
c
p
R t
 (1)
where Δp is the induced pressure, γs.l is the solid–liquid inter-
facial tension (i.e., material–water) and Rc(t) is the radius of 
curvature.
Hence, it is momentous to evaluate the suspected residual 
stabilizers in the starting PS-COOH nanoparticles (dispersed 
in highly purified water (HPW)), like PVA in the case of ali-
phatic polyesters by emulsion solvent extraction. First, using 
fast-acceptable sensitivity (i.e., energy-dispersive X-ray (EDX)) 
and routine (i.e., CHNS elemental or so-called oxygen combus-
tion) analysis, it seemed that the PS-COOH nanoparticles were 
totally clean from the suspected sulfate ester derivatives (e.g., 
sodium dodecyl sulfate (SDS), docusate sodium, etc.). Using 
CHNS analysis, only C and H elements were detected with the 
ratio of 89.37% versus 7.62%, attributed likely to C and H from 
PS-COOH molecules. However, when the starting PS-COOH 
nanoparticles were measured in the instrument with a lower 
limit of detection, i.e., inductively coupled plasma atomic emis-
sion spectroscopy (ICP-AES), it evidenced 520 ± 70 ppm sulfur 
(S) and 100 ± 50 ppm sodium (Na), likely associated to the 
existence of residual stabilizers, which may bestow remarkable 
nonspherical PS-COOH nanoparticles shape stability.
2.5. Comparison to Nonspherical Silica (SiO2) Nanoparticles
Because (mesoporous) nonspherical SiO2 nanoparticles are 
subject of many publications ranging from the manufacture 
until in vivo study,[52–56] nonspherical SiO2 nanoparticles were 
benchmarked to our nonspherical polymeric nanoparticles 
fabricated by film-stretching method. We synthesized two dif-
ferent aspect ratios (AR) of plain mesoporous nonspherical 
SiO2 nanoparticles, namely ≈3 (simulating the similar aspect 
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ratio and dimension with the stretched nanoparticles) and ≈8 
(Figure 6). From the shape stability aspect, both nonspherical 
SiO2 nanoparticles were excellent and superior against the 
most stable nonspherical PLGA 75/25-COOH manufactured 
by emulsion solvent extraction using PVA. The evidences were 
demonstrated by only slight diminution of aspect ratio, hydro-
dynamic size, and PDI after the storage in physiological-related 
condition for 29 d. The t1/2 values are more than 10 000 and 
13 000 d for aspect ratio 3 and 8, respectively (Figure 1e). The 
exceptional nonsphericity was in the same fashion as reported 
previously.[57] Simultaneously, zeta potential and pH of non-
spherical SiO2 nanoparticle preparation remained relatively 
stable (Figure 6).
Using the available instruments (i.e., differential scanning 
calorimeter (DSC) and thermogravimetric analysis (TGA)) and 
their working temperature range, neither liquefaction tempera-
ture (i.e., melting temperature (Tm)) nor other thermal events 
of nonspherical SiO2 nanoparticles could be detected. It was 
reported, nonetheless, the Tm of bulk SiO2 was 1600 °C.[58] 
Meanwhile, the Young’s modulus (bulk) and surface rough-
ness of bulk-mesoporous nanoparticle of SiO2 were reported 
73 GPa[59] and Rrms or Ra (average roughness) ≈2.5–10 nm,[60] 
respectively. The porosity and residual moisture of nonspherical 
SiO2 nanoparticles for the aspect ratio 3 were ≈12.98 m2 g−1 and 
2.47%, whereas for the aspect ratio 8 were 285.6 m2 g−1 and 
2.70% (Figure 1g). These values may be interpreted that the 
mechanical properties (the prodigious liquefaction tempera-
ture and Young’s Modulus, yet relatively smooth surface) and 
hydrophilicity of nonspherical SiO2 nanoparticles successfully 
overpowered the impressive porosity in relation to elicit the tre-
mendous nonspherical nanoparticle shape stability.
To further elucidate the hydrophobicity degree of SiO2, the 
Rose Bengal method was applied. As expected, the hydropho-
bicity of SiO2 (regardless of their aspect ratios) is much lower 
compared to the formerly tested polymers, characterized by 
virtually no Rose Bengal adsorption onto SiO2 particles. Conse-
quently, no graphic can be plotted like aliphatic polyesters, PS-
COOH, and gelatin nanoparticles in Figure 5d. Furthermore, 
“SiO2 bulk” (roughly represented by tetraethyl orthosilicate 
(TEOS), the monomer of SiO2 nanoparticles]) also exhibited 
relatively low hydrophobicity, displayed by high SFE about 
55 mN m−1, low material–water interfacial tension ≈3.8 mN m−1 
and WCA around 45° (Figure 5e). We suggest that both first 
parameters are better to be correlated with the nonspherical 
shape stability compared to merely WCA due to the absence of 
nonpolar or hydrophobic component consideration in WCA.
Likewise, residual stabilizer determination for PS-COOH 
nanoparticles, fast-acceptable methods (EDX and Fourier trans-
form Infrared [FTIR]) were employed to both nonspherical SiO2 
nanoparticles. The results demonstrated that no bromide peak 
from cetyltrimethylammonium bromide (CTAB) and a carbon 
chain band (wavenumber 3000–2800 cm−1) in the washed 
nonspherical SiO2 nanoparticles (data not shown), implying 
that both nanoparticles might be entirely clean from residual 
surfactants. The similar results concerning the absence of Br 
after several washing steps of nonspherical mesoporous SiO2 
nanoparticle were reported formerly.[54] Nevertheless, it is plau-
sible that the residual amount of CTAB is lower than limit of 
detection of the used technique. Therefore, oxygen combustion 
method was performed and revealed that C, H, and N elements 
existed in both aspect ratios of SiO2 nanoparticles with the ratio 
of about 1.00%, 3.12%, and 1.99%, respectively, but no Br was 
detected. To convince the residual CTAB in both nonspherical 
SiO2 nanoparticles, Br analysis was performed using an induc-
tively coupled plasma mass spectrometry (ICP-MS) and demon-
strated that more than 96.8 ppb Br were detected.
3. Discussions
Here, the study for nonspherical nanoparticles fabrication 
covers the bottom-up methods, encompassing cross-linking 
(physical and chemical), molecular entanglement (nanopre-
cipitation and emulsion solvent extraction), and polymeriza-
tion. We focus in these methods due to the potential thereof 
as the controlled release matrix. It is also possible to obtain 
nonspherical nanoparticles by diverse top-down methods (e.g., 
milling,[61] homogenization,[62] evaporative/antisolvent precipi-
tation/solvent-diffusion[63,64]), but these approaches are com-
monly intended to enhance the dissolution of drug substances 
due to the greater surface area of nonspherical nanoparticles 
compared to the spherical ones with the same volume (or so-
called: greater surface-to-volume ratio; Figure 1d).
Through the implementation of film-stretching method to 
the spherical nanoparticles (produced by the first two afore-
mentioned bottom-up methods), it is basically believed that 
the shape-memory programming is introduced to the nano-
particles.[65,66] The spherical nanoparticles may be regarded 
as a primary shape. Subsequently, the primary shape is then 
mechanically deformed into a secondary shape at tempera-
tures exceeding the bulk Tg (e.g., Table S1, Supporting Infor-
mation vs Figure 1f). In this work, it was undergone merely 
uniaxially (however, it was also reported the plausibility of 
biaxial stretching,[4,33,67,68] imparting much higher aspect ratio, 
surface area, and variation of radius of curvature (Rc(t)), but 
very low density of particle constituents (Supplemental Cal-
culation, Supporting Information) compared to the uniaxial 
one). Consequently, the sample is cooled below the bulk Tg, 
while still under stretching, to induce crystallization. Next, the 
secondary shape is preserved through an abrupt reduction in 
polymer chain mobility. Generally, the recovery to the primary 
shape in shape memory is then attained by simply heating the 
unconstrained network above dry bulk Tg. The resulting incre-
ment in polymer chain mobility permits the entropic energy 
lost during stretching to be converted into a restorative force 
that reestablishes the primary shape of the network. Neverthe-
less, we reported here that the recovery to the original state 
occurred below the bulk Tg (chiefly at physiologically relevant 
condition: 37 °C, PBS pH 7.4 310 mOsm), depending on the 
complex physicochemical parameters of bulk and fabricated 
nanoparticles.
In principle, it appears that by stretching or formation of 
nonspherical particles, the neater alignment of polymer chain 
arrangement in nanoparticle is formed. The higher order is, 
however, not favored thermodynamically. At higher tempera-
ture (e.g., 37 °C), the larger entropy is triggered, which may 
lead back the polymer chain to the preferable disorientation. 
The degree of polymer chain mobility, indicated by the rate of 
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Figure 6. a) Scanning electron micrographs obtained on different days after initial preparation displaying shape stability of plain nonspherical 
mesoporous SiO2 nanoparticles with the aspect ratio of ≈8 and ≈3. Nanoparticles were dispersed in phosphate buffer saline (PBS) pH 7.4 310 mOsm 
for a maximum of 90 d at 37 °C. Scale bars = 500 nm. Plots of b) aspect ratio (AR), c) hydrodynamic size, d) polydispersity index/PDI, e) zeta potential 
and f) final preparation pH of corresponding non-spherical mesoporous SiO2 nanoparticles.
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shape transformation into spheres in this report, is subject of 
multifarious physicochemical properties of bulk and fabricated 
nanoparticles (discussed in the following sections). On the con-
trary, as expected, nanoparticle storage at lower temperature 
(e.g., 5 °C) can aid to lessen the entropy level, thereby reduce 
dramatically the higher disorientation inclination of polymer 
chain arrangement. In other words, low storage temperature 
maintains longer the nonsphericity of nanoparticles.
3.1. Effect of Fabrication Method
3.1.1. Cross-Linking
In principle, the swelling of hydrogels (e.g., O-CMCHS and 
gelatin) at physiological pH (7.4) was very favorable, even for 
the highly (chemically) cross-linked hydrogel system as dem-
onstrated elsewhere.[69] It is due to the existence of charge 
from the isoelectric point (IEP) of the polymers (i.e., IEP of 
O-CMCHS: 2.0-4.0;[69] gelatin type B: 4.7–5.4[58]) at physio-
logical pH. We have tried to harvest both nonspherical cross-
linked hydrogel nanoparticles from PVA (Mowiol 40-88) film 
using only HPW (pH 5.5–5.8) as well, however, the exaggerate 
swelling still occurred (similar appearances like in Figure 1b). 
The considerable swelling in the nonspherical cross-linked 
hydrogel nanoparticles by the film-stretching method may 
be explained by the facts that swelling is more pronounced 
in the cases of smaller submicron (i.e., size ≤ 200 nm), less 
cross-linked (for O-CMCHS), and heated particles.[16,70] From 
these findings, it can also be inferred that swelling is actu-
ally displayed by hydrogel particles prepared by any materials 
(e.g., poly(hydroxyethyl acrylate) /PHEA, poly(ethylene glycol) 
diacrylate /PEGDA,[70] derivatives of hydroxyl PEG acrylate 
groups,[71,72] etc.) and methods (i.e., imprint lithography, irre-
spective from its subtypes,[16,70] particle replication in nonwet-
ting templates [PRINT],[71–76] etc.), but they are in the much 
lesser degree.
In our study, although the employed gelatin nanoparticles as 
prepared by Geh et al.[77] had been highly cross-linked (≈85%) 
using the standard chemical (covalent) cross-linker (i.e., gluta-
raldehyde), dramatic swelling thereof after embedment in PVA 
film matrix still took place (Figure 1b). This might be more 
associated with the heating history of gelatin nanoparticles in 
PVA film matrix (including its strong interaction with PVA 
as presented in the section “Results”) as well as its small sub-
micron size. Moreover, the strong interaction between hydro-
phobic part of gelatin and PVA was utilized to develop gelatin 
nanoparticles without crosslink.[78] The remarkable interac-
tion may also occur between PVA and other hydrogel systems, 
such as lithography (e.g., S-FIL,[14] J-FIL,[15,79] and D-FIL[16]) or 
PRINT®[71–73,75] method.
Nonetheless, the stretched gelatin nanoparticles had a 
slightly (far from ideal; Figure 1d) nonspherical (prolate) shape, 
favorably associated with the immediate shape transforma-
tion during harvesting and storage in physiological-related 
condition. This might be explained merely due to the greater 
hydrophobicity of gelatin bulk materials (higher than other 
protein, such as human serum albumin (HSA); Figure 5e) and 
nanoparticles (as exhibited in section “Results”). It is because 
in principle, the covalently cross-linked networks (like in 
gelatin nanoparticles) should show affine deformation toward 
stretching;[80] meaning it should behave likewise the thermo-
plastic polymers (e.g., aliphatic polyesters, polystyrene, etc.).[65] 
In the case of O-CMCHS owning the poorest nanoparticle non-
sphericity, it may rather be ascribed to the lack of nanoparticle 
integrity, due to the consideration of its high bulk hydrophi-
licity (Figure 5e) and Tg (140–150 °C).[81]
Regardless of the poor results of nonspherical cross-linked 
hydrogel nanoparticle shape stability, we also suggest that 
because of the exaggerate swelling, film-stretching method 
seemed inappropriate for the production of nonspherical 
cross-linked hydrogel nanoparticles. Hence, this paper remon-
strates the prior suggestion by Champion et al.[82] that the 
film-stretching method would be rather versatile for the non-
spherical nanoparticles fabrication using various bulk materials 
and nanoparticles. Nevertheless, film-stretching method may 
be still appropriate for other (more solid) cross-linked particles 
(e.g., poly(methyl methacrylate) [PMMA][83]).
For the manufacturing of milder swollen nonspherical 
hydrogel micro- and nanoparticles (which usually have low [but 
tunable] Young’s modulus[71–73]), imprint lithography or PRINT 
technology (a top-down method[84]) may provide more prom-
ising possibilities. However, certain component material(s) on 
both technologies are not biodegradable, e.g., PEGDA.[14,85] Fur-
thermore, and importantly, we should be aware and critical to 
the potential instability of their nonspherical shape in relation 
to the comprehensive manufacturing aspects, mainly the hydro-
phobic degree of particle component materials (Figure 5e). 
Some of examples of these system are discussed below.
For the first instance, the synthesis of moderately hydro-
phobic nonspherical (biconcave or complex oblate ellipsoid) 
hydrogel microparticles has been demonstrated (with the 
details: particle Young’s modulus 7.8–63.9 × 10−6 GPa;[73] con-
sisting of PHEA [≈up to 80% as main polymer], 2-carboxy-
ethyl acrylate/CEA [10% as negative charge bearing agent], 
and PEGDA [1–10% as cross-linker; bulk Young’s modulus: 
0.01–3 GPa[86]]). By virtue of deliberation of their comprehensive 
manufacturing aspects (i.e., low Young’s modulus, poor bulk Tg 
[likely <22 °C,[87] depending on the water content], and mod-
erate hydrophobicity of their components and final preparation 
[which may be comparable to aliphatic polyesters; Figure 5e]), 
we believe that this system is favorably to encounter shape 
transformation into spheres in physiological-related condi-
tion, even the transformation rate is possibly slower than at the 
nanoscale.[26] But, there was no report regarding its nonspher-
ical shape instability because they used 0.1% PVA (2 kDa) as 
dispersant that definitely stabilizes the shape of nonspherical 
microparticles (recall the case of our residual PVA results).
Second, PEGDA cross-linked by synthetic peptide (acrylated 
Gly–Phe–Leu–Gly–Lys/GFLGK) was employed to produce 
nonspherical hydrogel nanoparticles.[14] By using similar 
extensive approach as above, it is known that PEGDA nano-
particles have low, but tunable nanoparticle Young’s modulus 
0.255 × 10−6–3 GPa[86] (depending on cross-link density), poor 
bulk Tg (≈-34 °C, regardless of its cross-link density[88]), Tg con-
finement effect, small Rc(t), and mild-moderate hydrophobicity 
of their components. Based on these data, we propose that the 
nanoparticles may experience considerable nonspherical shape 
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instability in physiological-related condition. Our proposal is 
strongly evinced by the very rapid transformation of similar 
nonspherical nanoparticles into spheres after the contact of 
(unconstrained) particles with HPW.[89] Therefore, the omission 
of supposedly high amount of stabilizer (PVA 31 kDa) postsyn-
thesis process was performed.[14] From these two examples, it 
is noteworthy to point out that the presence of proper stabilizer 
exhibits the superior nonspherical particle shape stability.
Lately, instead of optimizing the commercially available sta-
bilizer and materials for supporting the excellent nonspherical 
particle shape stability, it is not surprising that the trend in 
finding and utilizing less hydrophobic novel polymers as par-
ticle core grows significantly. The eminent examples thereof 
encompass the members of hydroxyl PEG acrylate (HPA) 
group,[71] such as triethylene glycol monoacrylate (TEGA),[72,75] 
and tetraethylene glycol monoacrylate (HP4A).[74,76,90] Nev-
ertheless, these new polymers have bulk Tg much lower than 
their parent polymer PEGDA,[91] where the hydrophobicity 
is inversely proportional to the length of hydrophilic side 
groups[91] (e.g., i.e., Tg TEGA -48 °C[91] vs Tg PEGDA -34 °C[88]). 
Therefore, it will be very fascinating to investigate the best 
compromise between the hydrophobicity aspects and the other 
physicochemical properties (e.g., Tg, Young’s modulus, etc.).
3.1.2. Molecular Entanglement
To hinder excessive aggregation (principally during nanopre-
cipitation), the entanglement of polymer chain should be opti-
mized by an appropriate polymer molecular weight. Relatively 
low molecular weight polymer is highly recommended,[92] 
such as ≈17 kDa (as used here). The larger molecular weight 
(≈44 kDa) of PLGA 50/50-COOH is still proper for nanoprecipi-
tation process (which is in agreement as reported up to ≈61 kDa 
or 0.67 dL g−1 intrinsic viscosity[93]). However, the higher the 
polymer molecular weight by nanoprecipitation, the lower 
the nanoparticle yield due to the more aggregates formation 
(Table 1). The low-molecular-weight aliphatic polyester (17 kDa) 
might have surface active properties,[94] thereby permits better 
nanoparticle yield and integrity as well as compactness (low 
porosity). Therefore, it is not surprising that the higher porosity 
of aliphatic polyester nanoparticles (i.e., PLGA 50/50-COOH 
0.67 dL g−1) prepared by nanoprecipitation has been developed 
as “sponge” core for toxin entrapment.[95]
It is notorious that aliphatic polyesters[26,65] and PS(-COOH)[96] 
have shape-memory properties. For aliphatic polyesters, the 
shape-memory properties are more pronounced in the case of 
ester-ended variant, very low molecular weight (4.1 kDa) and 
very low bulk Tg (27 °C).[26] Whereas carboxyl-ended modifica-
tion has better solubility in water and physiological pH, thus 
enables lower interfacial tension to the nanoparticles during 
their dispersion on these media. It is also known that the 
smaller the particle size (at the submicron or nanoscale), the 
higher possibility and rate of shape change.[26,96] This finding 
is associated with the larger impact of interfacial tension at 
the nanoscale[26,96] and lower Rc(t) (Figure 1d). Even the shape 
shifting of pure macroscopic poly(styrene)/PS sheet (Rc(t) ∞) 
was reported at a temperature below its bulk Tg, viz. 60 °C[97] 
versus 100 °C,[23] consecutively.
From the “Results” section, it is very clear that the involve-
ment of particular stabilizer (only PVA [Mowiol 4-88] in the 
emulsion solvent extraction for PLA-COOH and PLGA 75/25-
COOH; sulfate ester in the emulsion polymerization for PS-
COOH; and CTAB in the condensation for SiO2) might result 
the meaningful residual stabilizers albeit thorough and strictly 
standardized washing process, leading to much superior non-
spherical nanoparticle shape stability in physiological-related 
condition. We believe and hypothesize that pure PS-COOH or 
PS nanoparticles (produced by surfactant-free process and in 
the same size range as tested here) may impart poorer non-
spherical shape stability in physiological-related condition due 
to their higher bulk hydrophobicity than the carboxyl-ended 
aliphatic polyesters (Figure 5e). Likewise, we suggest that the 
nonspherical shape stability may also occur in the case of non-
spherical core–(hydrophobic)shell systems having comparable 
or more inferior (e.g., Tg) physicochemical properties than 
materials tested here, such as cyanoacrylate–chitosan,[98] PLGA 
15/85–chitosan,[8,99] and PMMA–(PS–PDMS)[83] (poly(methyl 
methacrylate);poly(styrene);poly(dimethylsiloxane)) (Table 2 
and Figure 5e). However, there was no implicit report regarding 
the particle shape stability thereof because of the dispersion 
unavailability in physiological-related condition (e.g., 5 °C,[98] 
high stabilizer content,[83,100] constrained in [unreleased from] 
rigid matrix,[89] or in organic liquid[83]), too short observation 
time (e.g., 1 h [8]), and particle storage only at dry and room 
temperature. According to our confirmative study, it is true 
that by storage of nonspherical aliphatic polyester nanoparti-
cles at 25 °C (at ambient relative humidity) for 12 months in 
the constrained (unharvested) state in the PVA film, there was 
practically no aspect ratio decrease thereof (data not shown). To 
date, only few publications emphasize the plausibility of non-
spherical particle shape transformation in physiological-related 
condition.[26,85]
3.1.3. Uncompromisable Requisite of Hydrophilic and Strongly 
Attached Stabilizer for Hydrophobic Bulk Nanoparticles
To preserve the nonsphericity of nanoparticles, it was known 
that in the PRINT system, 0.1–0.5% PVA (with very high inter-
facial activity due to the low degree of hydrolysis [75%] with 2, 
20, or 22 kDa) is utilized intentionally as nanoparticle disper-
sant, including for in vivo study.[71–73,75,76,101] Instead of thor-
ough washing, others also preferred to keep the high amount of 
PVA (2% 31 kDa[14]) or give extra Poloxamer (such as 0.75%[102] 
or 1%[103]) as dispersant in final preparation to endow better 
nanoparticle stability and circulation time. Importantly, some 
extra dispersants actually might not help much to stabilize 
the nanoparticles in the real physiological environment due 
to the rigorous dilution of the dispersant and if the stabilizer 
easily detaches from the nanoparticle surfaces.[104] Hence, the 
additional stabilizer postnanoparticle formation is mandatory 
for stabilizers that are weakly bound onto nanoparticles, such 
as Poloxamer 407[103] on aliphatic polyester nanoparticles;[105] 
otherwise the stabilizers were too inadequate to protect the 
nanoparticles from opsonization. In the case of our study, it 
is very reasonable that the P407 stabilizer is extracted by PVA 
used as the film matrix due to its strong retention to PVA.[106] 
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Meanwhile, in case of TPGS, TPGS may have too low affinity 
(due to too hydrophilic) onto PLA-COOH nanoparticles, as 
reported elsewhere.[106,107] In-depth discussion of residual stabi-
lizers is presented in the section “Discussion: Effect of Hydro-
phobicity of Materials & Particles.”
3.2. Effect of Mechanical Properties: Young’s Modulus,  
Surface Roughness (Rrms) and Tg
In principle, roughness (surface topography) correlates with 
the hydrophobicity (surface energy/surface chemistry) and wet-
tability (WCA).[37] The impact of surface roughness may seem 
trivial, but our results showed its significance (recall the shape 
instability of rough nonspherical PLGA 50/50 by nanoprecipita-
tion). Due to the necessity of sophisticated instrument for par-
ticle’s roughness measurement (e.g., AFM), only a few papers 
have reported the influence of surface roughness to physi-
ologically relevant phenomenon, e.g., protein adsorption[108] or 
so-called corona. This phenomenon gets more and more spot-
lights[109] because of its high correlation into clinical effect.[110,111]
Confinement effect was proved to be affected by the inter-
facial activities (in decreasing phase transition [including liq-
uefaction] temperature of confined materials, irrespective of 
object geometry), existence of residual stabilizers, and kind of 
dispersion media.[41,112,113] Atoms at a free surface (such as in 
nanoparticles) encounter a diverse local milieu than do atoms 
in the bulk material. As a consequence, the energy related to 
these atoms will commonly be different from the atoms in the 
bulk. The additional energy linked with surface atoms is called 
SFE. In bulk materials, such SFE is characteristically ignored 
because it is attributed with merely a few layers of atoms near 
the surface and the ratio of the volume occupied by the surface 
atoms and the total volume of material of interest is low. Con-
versely, for smaller objects, the surface-to-volume ratio becomes 
very significant, and so does the effect of SFE.[36]
In general, macroscale objects have virtually no tendency to 
experience confinement effect compared to microscale[85,114] 
and nanoscale[36,42] objects. This trend may be ascribed to 
the higher surface-to-volume ratio of the nanoscale objects. 
Strong confinement effect on phase transition (e.g., liquefac-
tion [Tg and Tm]) temperatures in nanoscale objects or radius 
of curvature does not only occur on polymeric systems (as 
reported here and elsewhere[41,42]), but also on any materials, 
both nonmetallic (e.g., water,[51] lipid,[115,116] etc.) and metallic 
ones (e.g., gold [Au],[117,118] lead [Pb],[119] tin [Sn],[119] bismuth 
[Bi],[119] etc.). Interestingly, it was reported that even in macro-
scale, certain polymer cases, such as bulk aliphatic polyesters, 
were also prone to the reduction of Tg due to absorption of non-
freezable water.[39,40] However, to our best knowledge, there is 
still no report discussing the relation between Tg confinement 
effect and nonspherical particle shape stability. Therefore, this 
report is the first one which proposes to correlate thereof. Nev-
ertheless, it has been actually reported the shape evolution 
from the nonspherical to spherical nanoparticles on aliphatic 
polyester derivative (i.e., PEG block copolymer)–microparticles 
(initial Feret’s diameter ≈ 50 µm)[85] and aliphatic polyester 
micro-nanoparticles (initial and final sphere ø 0.15–4 µm).[26] 
The PEG–aliphatic polyester block copolymer (having a lower 
bulk Tg than its native aliphatic polyester) was also described 
to encounter the Tg confinement effect.[120] Both reports used 
stabilizers during the nanoparticle formation, i.e., polysorbate 
(Tween) 20 (0.5%) during the washing step for the former and 
PVA (2%; molecular weight 10–30 kDa) during the solvent dif-
fusion (also known as emulsion solvent extraction) process. 
The plausible rationale of residual stabilizers will be discussed 
deeper in the section “Results: Effect of Hydrophobicity of 
Materials & Particles.”
For nanoprecipitation system (containing only aliphatic 
polyesters), the smaller Young’s modulus and Tg are ascribed 
to merely confinement effect due to the smaller size (width 
and height) of nanoparticles and presence of very low Rc(t) 
(Figure 1d). Meanwhile, in the emulsion solvent extraction con-
taining significant residual PVA, the slightly higher of mechan-
ical properties are designated to the PVA, which is semicrys-
talline[121,122] and gains higher crystallinity after stretching.[123] 
It was also obviously observed the slightly growth of formula-
tion’s Tg of nanoparticles containing residual PVA due to anti-
plasticization effect, as reported elsewhere.[124] As comparison, 
in case of the presence of amorphous and crystalline variants 
in a polymer (e.g., polyethylene terephtalate (PET)[125] or poly-
propylene (PP)[126]), polymer stretching generally increases 
Tg and Young’s modulus several folds because of crystallinity 
enhancement.
In many cases, residual stabilizers can also be problem-
atic due to the decline of particle’s Tg in final preparation. 
Although some other common stabilizers (Poloxamer,[105,127] 
TPGS,[128] cholic acid in sodium salt form,[129] and polysorbate 
[Tween] 80[130]) are practically easy to be cleaned from parti-
cles, but in an adequate amount in the final preparation, 
they are reported to lessen the system Tg. The Tg reduction is 
well known as the presumable main reason of burst release 
in drug delivery.[131] In our formulation, the insignificant 
amount of resided Poloxamer 407 and TPGS is well repre-
sented as the insignificant changes of formulation Tg (data 
not shown). It was reported when acting as stabilizer, TPGS 
would distribute only on the particle surface and by washing 
up more than two times, the remaining TPGS on the surface 
could not be detected anymore by X-ray photoelectron spec-
troscopy (XPS).[132,133] This may be the proper explanation for 
the poor protection of TPGS for nonspherical PLA-COOH 
nanoparticles fabricated by emulsion solvent extraction. In 
contrary, the particular amount and type of PVA (possessing 
high interfacial activity) could adhere irreversibly on particles 
surface prepared by emulsion solvent extraction via molecular 
interpenetration and multilayer adsorption mechanism,[134] 
thus affects particle’s physical properties (including drug 
release from nanoparticles) and cellular uptake.[135,136] Inter-
estingly, with regard to the residual stabilizers, the affinity 
and extent of residual PVA, Poloxamer, and TPGS on aliphatic 
polyester nanoparticles prepared by emulsion solvent extrac-
tion can also be differentiated from the freeze-drying results 
in HPW and without additional cryoprotectant (our unpub-
lished data; in preparation). Only PVA could elicit sponta-
neous redispersion and practically no aggregation, which can 
be assigned as the sufficient amount and strong adsorption 
of PVA on nanoparticles. The aggregation degree of nanopar-
ticles synthesized by the aid of Poloxamer 407 and TPGS is 
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as inferior as the nanoparticles prepared by nanoprecipitation 
(no stabilizer). These results are in agreement with previous 
publications using other materials and shapes of nanoparti-
cles.[127,132,137] Based on the experimental results, we propose 
a systematic approach to better explain and predict the non-
washability of particular stabilizers, as depicted in-depth in 
the section “Discussion: Effect of Hydrophobicity of Materials 
& Particles.”
3.2.1. Reverse Proof of Complex Physicochemical  
Properties Interplays
First instance: Successful Stretching at the Temperature Below 
Bulk Tg Using Nanoparticles Composed of Low Young’s Modulus, 
but High Tg Material: Palazzo et al.[98] interestingly reported 
that the manufacture of nonspherical nanoparticles using 
film-stretching method uniaxially could be undergone far 
(≈50–100 °C) below the bulk Tg of the polymer (Table 2). To 
our best knowledge, only this paper reports the success of 
film-stretching method below the Tg.[138] Others[4,13,68,139] 
(including this report) always employ the temperature higher 
(normally ≈20–30 °C) than the bulk Tg, regardless of the 
used stretching medium (dry heating or oil bath) and nano-
particle materials. Moreover, Lu et al.[138] should perform the 
stretching ≈100 °C higher than the Tg due to their device limi-
tation. Palazzo et al. works might be feasible because of the 
low Young’s modulus of the used materials (cyanoacrylate: 
i.e., poly(isobutylcyanoacrylate) [PIBCA] & chitosan; both 
≈0.002 GPa; Table 2). We do not believe the reason that Tg 
confinement effect could be applied to explain it, because our 
works convincingly showed the inability to stretch PS-COOH 
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Table 2. Physicochemical contrast of nonspherical polymeric core–shell nanoparticles prepared by film-stretching method (PIBCA, 
poly(isobutylcyanoacrylate); PLGA, poly(d,l-lactic-co-glycolic acid); PMMA, poly(methyl methacrylate); PS, poly(styrene); PDMS, poly(dimethylsiloxane)).
Parameters Example
1 2 3
Component Core Shell Core Shell Core Shell
Material Cyanoacrylate 
(PIBCA)
Chitosan 
(low viscosity)
PLGA 15/85 Chitosan PMMA PS–PDMS 
(block copolymer)
(Degradex from Phosphorex, Inc.,  
Hopkinton, USA)
Reported in reference(s) [98] [8,99] [83]
Young’s modulus [GPa] ≈0.002[242] 0.002–0.003[243] N/Aa) ≈0.002[243] ≈3[23] PS 3.2–3.4[23]
PDMS 0.36–0.87[244]
Tg [°C] Bulk 130
[245] Bulk ≈100–150[81] Nanoparticle 40–41[8,99]
Bulk N/Aa)
Bulk ≈100–150[81] Bulk 106–113[23] PS bulk 100[23]
PDMS bulk ≈123–150[23]
Bulk hydrophobicity Refer to Figure 5e Refer to Figure 5e – Refer to Figure 5e Refer to Figure 5e Refer to Figure 5e
Positive remarks • High bulk Tg (PIBCA & Chitosan)
• Dry heat stretching procedure
•  Further information availability  
of chitosan properties
• High bulk Tg (Chitosan) •  Intermediate (PS) & high (PMMA < PDMS) 
bulk Tg
•  Intermediate (PDMS) & relatively high 
Young’s modulus (PS & PMMA)
• Dry heat stretching procedure
•  A little information availability of washing 
process & used polymer molecular weight
Negative remarks •  High hydrophobicity (PIBCA  
slightly < chitosan slightly < gelatin)
•  Very low Young’s modulus  
(PIBCA ≈ Chitosan)
•  Very low bulk Tg & relatively lower Young’s 
modulus of PLGA 15/85 (due to high  
glycolide percentage)[58]
• Very low Young’s modulus (Chitosan)
• Low wet Tg (nanoparticles)
•  Oil bath during stretching (thus, involvement 
of additional potential contaminants  
& organic solvent)
•  Great hydrophobicity (PMMA ≈< PS slightly 
< PDMS)
Unknown information • Residual stabilizer amount
•  Details of washing process (including  
washing & redispersion factor)
• Details of PIBCA (e.g., molecular weight)
•  Nanoparticle integrity  
(∼porosity ∼residual moisture)
• Surface roughness
• Nanoparticle hydrophobicity
•  Residual stabilizer amount
•  Details of washing process (including  
washing & redispersion factor)
•  Details of core-shell materials (e.g.,  
molecular weight)
•  Nanoparticle integrity (∼porosity ∼residual 
moisture)
• Surface roughness
• Nanoparticle hydrophobicity
• Residual stabilizer amount
• More about washing & redispersion factor
•  Nanoparticle integrity (∼porosity ∼residual 
moisture)
• Surface roughness
• Nanoparticle hydrophobicity
a)N/A, Not available.
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nanoparticles (the highest nanoparticle Young’s modulus that 
can be stretched in our study: ≈2 GPa; Figure 1f), even at its 
bulk Tg (Figure S3, Supporting Information). Conversely, ours 
confirmed that Tg should vary in diverse medium, as reported 
elsewhere.[113]
Nevertheless, we still can infer that the obvious interplay 
presence between Young’s modulus and Tg yielded the cer-
tain resistance for stretching process (Figure S3, Supporting 
Information). In this case, although bulk Tg of PS-COOH 
(≈93 °C; Figure 1g) is much lower than both bulk Tg in 
Palazzo’s work (in-between ≈100–150 °C; Table 2), PS-COOH 
nanoparticles cannot be proportionally stretched as our 
standard stretching process at 120 °C (Figure 2). Moreover, 
stretching PS-COOH nanoparticles at its bulk Tg only gen-
erate lemon-like nanoparticles partially from total nanopar-
ticle population (Figure S3, Supporting Information). Our 
generated shape resembles the nanoparticle shape produced 
by them. This shape might be attributed to the weak elastic 
deformation because of the high resistance from polymer 
chain mobility in nanoparticles. In addition, because of high 
bulk (cyanoacrylate and chitosan) hydrophobicity, high mate-
rial–water interfacial tension may also induce the nanopar-
ticle shape switch during harvesting in aqueous medium 
(Figure 5e).
Second Instance: Unsuccessful Stretching at the Tempera-
ture Far Above Bulk Tg Using Nanoparticles composed of High 
Young’s Modulus, but Low Tg Material: Cauchois[140] reported 
his failure to stretch spherical poly(γ-benzyl-l-glutamate) 
(PBLG) nanoparticles using film-stretching method. PBLG, 
a rigid[141] liquid crystalline material, has an unique (hel-
ical) internal structure, thus may exhibit either spherical 
or elongated particles, depending on its variants.[142] It 
has rather high hydrophobicity (in-between PLA-COOH 
& PLGA 75/25-COOH; Figure 5e), bulk Young’s modulus 
34 GPa,[143] and Tg ≈ 19 °C.[144] He found out that even 
the stretching process was performed at the temperature 
(i.e., 150°) far above the bulk Tg, spherical PBLG nano-
particles were unsuccessful to be deformed into the elon-
gated ones.[142] The hydrogen bond, which should take 
an account as the main driving force in transforming 
stretched particles,[12] seems work limitedly for soft material 
(<10 GPa[145]), such as PS and PMMA.[83] To sum up, the 
Young’s modulus of particles appears also to be one of a 
critical factor (besides Tg) determining the success of film-
stretching method.
Based on both instances, we can conclude that the unavoid-
able interplay between multiple factors (Young’s modulus, Tg, 
and surface chemistry) determines the deformability degree 
of nanoparticles (in this section, it is characterized by the suc-
cess degree of nonspherical nanoparticle formation by film-
stretching method). We estimate that the deformability degree 
in the film-stretching method may favorably represent (but of 
course, still less a couple order of magnitude) the geometry 
sensitiveness of nonspherical nanoparticles in the real aqueous 
dispersion toward the interfacial tension. Therefore, these evi-
dences reinforce our hypothesis that the complex interplay of 
manufacturing aspects may affect the nonspherical nanopar-
ticle stability. We cannot only concern in one-two aspect(s) and 
neglect the others.
3.2.2. Correlation of Interfacial Phenomena towards Geometry  
and Internal Structure
Because of the interfacial tension, spherical particles (having 
no specific internal structure (like all experimented here using 
wide angle X-ray diffractometry, data not shown) or merely 
amorphous state in nature) are formed thermodynamically 
from nonspherical particles in order to minimize the con-
tact area to water (recall the relative surface area comparison 
of the same volume objects, but different shape in Figure 1d 
and Supplemental Calculation, Supporting Information). This 
phenomenon arises from the energetic cost of forming a sur-
face. Therefore, the SFE of the system is minimized when the 
particle shape is spherical. Besides, spherical state may permit 
polymer chain inside nanoparticles to have larger cohesive 
energy.[146,147] Meanwhile, the greater surface area of nonspher-
ical state (and the contribution of very low Rc(t)) will introduce 
more pronounced interfacial tension eliciting higher pressure. 
Consequently, the pressure would play a dominant role in the 
enhancement of polymer chain mobility on the surface, leading 
to the particle shape shifting into spheres.[148] To summarize, 
here is the condensed hypothesized correlation: the higher the 
hydrophobicity of materials/nanoparticles, the higher the inter-
facial tension, the higher the pressure working on nanopar-
ticle surface, the faster the shape transformation into spheres. 
In brief, there is a sturdy relation between surface chemistry 
(hydrophobicity) and nonspherical shape stability/existence, as 
long as no robust or rigid internal structure. Our hypothesis is 
described on the next following examples.
First, beside well-defined amorphous aliphatic polyesters and 
PS-COOH studied here, another best example for the aforemen-
tioned hypothesis is poly(4-vinyl pyridine) (P4VP), an amor-
phous and a weakly hydrophilic polymer (Figure 5e). Likewise 
the aliphatic polyesters, P4VP (grafted by PS) exhibits shape-
memory properties depending on media pH.[149–151] In contrast 
to aliphatic polyesters, the P4VP hydrophobicity becomes lesser 
at pH lower than its pKa (5.5) and reaches maximum at higher 
pH.[149,151] Therefore, these findings are recently employed to 
produce a pH-sensitive block copolymer with polystyrene (PS-
b-P4VP).[149,150] In accordance with our interfacial activity data-
base (Figure 5e) and other aspects of P4VP (bulk Young’s Mod-
ulus 4.05 GPa[152] and Tg 142 °C[23]) and PS, it may be plausible 
that the nonspherical/elongated (so-called pupa-like) particles 
made from PS-b-P4VP may demonstrate relaxation into the 
spherical ones in physiological-related condition.[149] Our sug-
gestion relies on the report by Deng et al.[150] revealing three 
key points that also fully support our hypothesis: a) addition 
of higher amount PVA (0.1%; 13–23 kDa and 88% hydrolyzed) 
during the manufacturing is indispensable for the greater nan-
oparticle hydrophilicity and thus, abundance of nonspherical 
nanoparticles; b) weak elongated internal structure exhibited 
by PS-b-P4VP (each material component Young’s modulus 
≈<4 GPa) can only be demonstrated with the considerable 
amount of PVA; and c) higher hydrophobicity caused by the 
incorporation of hydrophobic gold (Au) ≈40% (Figure 5e; bulk 
Young’s modulus ≈65 GPa[153] and Tm 1064°C[154]) results the 
plumper nanoparticles (decrease of aspect ratio).
Second, to give a diverse/contrary approach, the tunably 
amphiphilic (SFE ≈ 22–45 mN m−1)[155] poly(2-oxazoline) family 
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was demonstrated. The increase of nanoparticle hydrophobicity 
by the incorporation of hydrophobic drug (i.e., Docetaxel (logP 
2.4[156]) or Paclitaxel (logP 3.24[156]) into the amphiphilic worm-
like poly(2-oxazoline) micelles (or so-called “filomicelles;” 
bulk Young’s modulus ≈2–20s × 10−6 GPa[157] and bulk Tg ≈ 
80 °C[155])) is proven to trigger an immediate transformation of 
nonspherical nanoparticles into spherical nanoparticles.[158] The 
higher the hydrophobicity induced by the particular drug (i.e., 
Paclitaxel) and higher drug loading (leading to larger particle–
water interfacial tension), the more spontaneous and entire the 
spherical shape switch. In contrary to our current results dis-
playing the preferable transformation from nonspherical into 
spherical particles during storage, Schulz et al.[158,159] reported 
that their drug-loaded nanoparticles turned gradually from 
spherical into worm-like particles due to the release of hydro-
phobic drug from nanoparticles (up to ≈60% for 25 d). Their 
observation was conducted at room temperature (≈25 °C) and 
37 °C[159] (far below the drug loaded-nanoparticle Tg 73–76 °C) 
and in physiological-related medium (phosphate buffer saline 
[PBS] pH 7.4 310 mOsm).
Third, for nanoparticles having its own definite internal 
structure, large interfacial tension because of high hydro-
phobicity or very low Young’s modulus could be simply over-
come. As a consequence, they may generate superior shape 
stability[142] or even, nonspherical nanoparticles spontaneously 
from the spheres over time.[115,160–163]
The former example is represented by PBLG.[142] Because of 
its superior Young’s modulus and comparable hydrophobicity 
to PLA-COOH and PLGA 75/25-COOH (details are referred 
to the previous subsection “Reverse Proof of Complex Phys-
icochemical Properties Interplays”), it is very plausible that 
the nonsphericity of PBLG nanoparticles may stay longer in 
an aqueous dispersion in physiological-related condition. The 
lower bulk Tg of PBLG does not appear to significantly induce 
the nonspherical shape instability.
Whereas the latter instance is exhibited by the crystalline 
lipids (e.g., triglycerides) in spherical solid lipid nanoparticles, 
which is stored in aqueous medium at room temperature.[163,164] 
Triglyceride has high degree of hydrophobicity (Figure 5e; 
represented as cocoa butter[58]), bulk Young’s modulus ≈0.25–
0.47 × 10−6 GPa,[165] and average Tm 31–34 °C[58] (actual Tm 
ranging 11-73 °C[116] due to the variation of trilaurin-tristearin 
as well as α- & β-polymorph). Considering these unsupportive 
properties for nonsphericity, it is really astonishing to know 
that triglyceride nanoparticles can arrange themselves into non-
spherical nanoparticles during storage. It is likely because of 
the necessity to have as high as possible cohesiveness[146] and 
density of crystal lattice.[164] In fact, the internal nonspherical 
(e.g., rod) crystal habit in nanoparticles can accommodate these 
needs through the formation of certain internal structure, i.e., 
stable β-polymorph.[115,160,161]
However, because both nonspherical PBLG and triglyceride 
nanoparticles already have the highest thermodynamic stability 
and molecular compactness, they may impart very poor drug 
loading[164,166] and final preparation quality. These situations 
are absolutely unexpected for drug delivery. In the future, we 
believe that the excellent compromise of shape factor and other 
manufacturing aspects will become the key issues to be han-
dled. Additionally, in accordance with the findings described 
in this section and our entire results, we can conclude that the 
internal structure is principally the most influential aspect in 
determining the longevity of nanoparticle shape, then followed 
by surface chemistry (bulk-nanoparticle hydrophobicity; which 
can be further divided into: residual stabilizers, core–shell 
structure, and not to mention surface roughness), and next 
by Tg-Young’s modulus (nanoparticle integrity) in the equal 
position.
3.3. Effect of Porosity of Particles
In many cases, porosity may correlate inversely with the 
Young’s modulus. It can be reflected from the relation of 
porosity (Figure 1g) and Young’s modulus (Figure 1f) on nano-
particles prepared without any stabilizer or surfactant. The two 
most porous nanoparticles in this group (i.e., PLGA 50/50-
COOH and gelatin) have the smallest Young’s modulus. This 
trend was same as reported elsewhere.[167] These two factors 
appeared to be the additional inducers (beside surface rough-
ness) to explain the poor nonspherical stability of PLGA 50/50-
COOH nanoparticles by nanoprecipitation.
The degree of SSA gain depends on the type and concen-
tration of used stabilizer[168,169] as well as sort of organic sol-
vent.[170] These parameters are the renowned defining factors 
impacting the mechanical and hydrophobic properties of nano-
particles, thus also potentially affect the nonspherical nanopar-
ticle shape stability. In addition, it has been studied the effect of 
diverse nanoparticle porosities[56,171] to the physiological-related 
events, such as protein adsorption.
The behavior of water absorbed into nanoparticles (displayed 
by the residual moisture) may be associated with various rea-
sons, e.g., the effect of capillary condensation, the confinement 
of water by polymer structure, the formation of clusters, or the 
strong interactions between the highly bipolar water molecules 
and the polymer polar groups.[40]
3.4. Effect of Hydrophobicity of Materials and Particles
The presence of hardly removed residual stabilizers (usually 
surfactants) appears to be uncompromised for keeping the 
nonsphericity of nanoparticles in aqueous and/or physiological 
medium, chiefly when the bulk material is hydrophobic. Our 
hypothesis is totally based on our current experimental data 
and well supported by other references as discussed below.
3.4.1. Aliphatic Polyesters and Residual Stabilizers Thereof
For the first example PVA (Mowiol 4-88), an amphiphilic sta-
bilizer (which was added in the emulsion solvent extraction 
process for aliphatic polyester nanoparticles preparation) and 
commonly used in the colloidal suspension, plays an impor-
tant role in maintaining significantly longer the nonspherical 
nanoparticle shape stability. It is very interesting because the 
resulted nonspherical nanoparticles had been thoroughly 
washed. This may be explained that PVA molecules are sup-
posed to stay at the nanoparticle–water interface after their 
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work to decrease the interfacial tension (i.e., nanoparticle sur-
face energy per unit area) during the initial nanoparticle for-
mation. It has also been reported that PVA may be adsorbed 
or tightly associated with the surface layer and thus cannot be 
completely removed from the surface of nanoparticles.[50,105,135] 
In general, PVA has been preferentially chosen as emulsifier 
in nanoparticles fabrication due to its excellent stabilizing 
ability to avoid particles aggregation during postpreparative 
steps (e.g., freeze-drying and purifying), high yield of dry 
particles powder, and ease to be redispersed in solution after 
lyophilization.[127] But, the interest of PVA use in biodegrad-
able nanoparticle formation was rather low because of the 
reported health risk caused by PVA.[172] Nevertheless, recently 
PVA’s safety profile is vindicated and acknowledged as “accept-
able.”[173] As a consequence, PVA is now already approved for 
several injection products by US Food and Drug Administra-
tion (FDA).[174]
In our results, residual PVA might arise dominantly from 
Mowiol 4-88 (stabilizer in emulsion solvent extraction method) 
instead of Mowiol 40-88 (matrix for film-stretching). This was 
confirmed by virtually no additional PVA adsorption onto 
nanoparticle surface after stretching and thorough washing 
of nonspherical aliphatic polyester nanoparticles fabricated by 
nanoprecipitation (Figure 5d), thus no improvement of non-
spherical shape stability for aliphatic polyester nanoparticles 
fabricated by nanoprecipitation as well (Figure 1d). In con-
trary, the PVA content in aliphatic polyester nanoparticles was 
remarkably higher (Figure 5d). The disparity of PVA adsorp-
tion may be delineated by the interfacial activity variance of 
these PVAs,[121] beside the probable higher propulsion force 
inducing PVA entrapment during the nanoparticle forma-
tion. Mowiol 4-88 (stabilizer), the quite low molecular weight 
(31 kDa) PVA with the degree of hydrolysis 88%, has surface 
tension ≈45 mN m−1 at critical micelle concentration (CMC) 
0.5% (our results were in accordance with the manufacturer), 
meaning quite high interfacial activity. This makes it as an 
exceptional stabilizer for dispersed system.[121] Hence, it was 
not surprising that Mowiol 4-88 is chosen one the most com-
monly used PVA in the production of biodegradable nanopar-
ticles.[2,175] Whereas Mowiol 40-88, the large molecular weight 
(205 kDa) variant of PVA with degree of hydrolysis 88%, gener-
ates surface tension ≈54 mN m−1 at CMC 0.5%, which can be 
attributed to the relatively smaller interfacial activity. This fact 
may provide reliable reasons: a) why Mowiol 40-88 penetration 
and binding to the aliphatic polyester or compact nanoparticles 
are low and b) why it still can disrupt and strongly attach to the 
hydrophobic gelatin nanoparticles. In general, the lower mole-
cular weight and degree of hydrolysis of PVA impart higher 
interfacial activity.[121]
According to our results, it is highly recommended to dis-
close the stabilizer details (e.g., for PVA, at least the informa-
tion of molecular weight and degree of hydrolysis are vital to 
foretell the interfacial activity). Otherwise, the residue thereof 
becomes more uncertain and uncontrollable. However, some 
publications tend to disguise the information partly[176,177] or 
totally,[178,179] likely due to the confidentiality issue.
Besides, the unclear details of nanoparticle materials ema-
nate as well. For example, some papers did not state clearly the 
molecular weight (/intrinsic viscosity)[177] and/or end group[180] 
of used aliphatic polyesters; whereas these material proper-
ties are some of the determining factors for hydrophobicity. 
Our study and others[50] have shown clearly that the higher 
the hydrophobicity, the higher residual PVA, thus it may really 
modulate the nonspherical nanoparticle shape stability.
Furthermore, it is also really important to state the exact 
details of nanoparticle washing step (e.g., for centrifugation, it 
includes: the condition (speed and temperature), exact centrifu-
gation cycle number and dilution factor; as well as dispersing 
energy[181]) during their synthesis. It was reported that the 
residual stabilizers on the nanoparticles are very determined 
by the degree of washing.[107,182] There are, however, practically 
no publications stating obviously all details of washing steps, 
and here, we propose to cope with it. The unknown washing 
step details make residual stabilizer issue more challenging 
and unpredictable. Of course, this issue is extremely critical for 
nonspherical shape stability.
Based on above findings, we can infer that the detail descrip-
tions of employed materials (i.e., stabilizers and polymers) and 
washing steps in nanoparticle formation are very essential and 
should be declared as explicit as possible.
3.4.2. PS-COOH and Residual Stabilizers Thereof
The second residual stabilizers are based on the results of 
PS-COOH nanoparticles. It is very reasonable that no sig-
nificant shape alteration is reported for elongated PS nano-
particles[4,6,13,19,83] because the nanoparticles may contain 
considerable amount of residual surfactants.[43,183] Although 
some commercial nanoparticle products contain surfactants 
as stabilizers, sometimes the manufacturers refuse to disclose 
the chemical nature of the surfactant used.[184] Only few studies 
(including ours) successfully characterized the concealed sur-
factant by manufacturer, such as sulfate salt surfactant in PS 
nanoparticles.[43]
3.4.3. Silica (SiO2) and Residual Stabilizers Thereof
Beside our results, it was also reported that considerable 
amount of surfactant (i.e., CTAB) was left on nonspherical 
SiO2 nanoparticles compared to spherical ones.[53] Li et al.[55] 
observed as well that besides good resistance of nonsphericity, 
the residual surfactants on nonspherical SiO2 nanoparticles 
might help nanoparticles to be less degraded in simulated body 
fluids, such as gastric, intestinal, and blood. Also, they observed 
that the larger aspect ratio the nanoparticles, the more stable 
the nanoparticles against degradation in simulated body fluids. 
Based on this result, the larger aspect ratio might be correlated 
to the higher residual surfactants, protecting from harsh pres-
sure effect of water.
3.4.4. Related Issue of Residual Stabilizers
By applying film-stretching method, it is very reasonable that 
the configuration of residual (semicrystalline polymeric;, e.g., 
PVA [in our study], PEG [3000–20 000],[185] poloxamer,[186] etc.) 
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stabilizers alters significantly, such as from “mushroom” to 
“brush” (Figure 1a). The configuration alteration is attributed 
to our results that all stretched nanoparticles roughened after 
stretching [Figures 1f, 5a,b]). The “brush” conformation is 
renowned for much lower hydrophobicity because of thicker 
polymeric layer.[187] It was reported that the stretching of the 
polymer chains perpendicular to the surface leads to several 
new physical phenomena, including higher hydrophilicity.[187] 
Nevertheless, it is also important to note that film-stretching 
method can yield lower total system density as a result of sur-
face area growth, leading to lesser protection by stabilizer at the 
interface (Figure 1d). It is prominent that lower density at the 
interface may cause the “mushroom” conformation.[188] There-
fore, we suggest that the dynamic transition from “brush” to 
“mushroom” conformation does exist in the nonspherical par-
ticles manufactured by stretching method. This transition is in 
the contrary as usually reported in the spherical nanoparticles 
(from “mushroom” to “brush”).[189]
In general, it appears convincingly that the density factor 
is slightly more dominant than conformation aspect. The 
most recent evidence is that the higher degree of stretching 
(including biaxial than uniaxial stretching; see Figure 1d and 
Supplemental Calculation, Supporting Information), the more 
likely the increase of hydrophobicity, thus resulting the lower 
C3 complement adsorption.[4] It is well known that C3 comple-
ment has greater adsorption propensity to more hydrophilic 
surface.[111,190] C3 behavior is quite anomalous, whereas the 
majority of opsonins exhibits faster and higher adsorption to 
more hydrophobic objects.[191]
Residual stabilizer issue is frequently underestimated[192] 
and misconstrued.[193] In the former case, it has been reported 
that the researchers claimed to use the “uncoated” nanoparti-
cles. However, they actually used 1% PVA (without any further 
specification) on their formula.[192] Therefore, the definition of 
“uncoated” nanoparticles should be standardized to minimize 
the misleading and misinterpretation of experimental results 
caused by the unintentional nescience. In the latter case, nev-
ertheless the study objective is good (i.e., to see the synergistic 
between nanoparticle surface properties and in vitro related 
outcome [cytotoxicity enhancement of doxorubicin]), it is likely 
that the cancer cell culture study using aliphatic polyester nano-
particles produced by emulsion solvent extraction elicit bias 
results because of the unwary washing step (very likely just 
one time) and the usage of great amount of certain stabilizers 
above CMC (i.e., Cremophor EL, Solutol HS 15, and Tween 80; 
in-between one-to-three orders of magnitude). Our speculation 
is based on another report[194] and our stabilizer physicochem-
ical properties analysis (Table 3; further discussed in the next 
section); where these two stabilizers are very plausible to not 
present at the interface, thus detach easily from hydrophobic 
aliphatic polyester nanoparticles.
Furthermore, it is also important to note that toxicity can 
arise from residual stabilizers on a nanoparticle synthesis. 
However, on many occasions complete depletion of these 
residues is often difficult and sometimes impossible. The 
degree of stabilizer removal depends strongly to its affinity 
into nanoparticle matrix. For example, CTAB, which has rel-
atively intermediate-high surface polarity (≈0.53) compared 
to other stabilizers (Figure 5e), is difficult to remove from 
hydrophilic matrix, such as silica[195] (Figure S4, Supporting 
Information). It was reported that thorough CTAB elimination 
may lead to aggregation of the nanoparticles.[196] The strongly 
positive charge of CTAB adsorbed onto the surface of nano-
particles can trigger cytotoxicity and rapid opsonization, suc-
ceeded by MPS clearance.[197] As a consequence, many novel 
manufacturing methods involving materials extracted from 
natural sources as a novel stabilizers (e.g., HSA, bovine serum 
albumin (BSA), etc.) have been studied to produce various 
core nanoparticle materials, such as aliphatic polyester[134] and 
gold.[198]
Additionally, the affinity of stabilizer onto nanoparticle sur-
face may also be influenced by pH in the particular ionic sta-
bilizers (Table 3; logD), such as sodium cholate, sodium deoxy-
cholate, and Solutol HS 15. Nevertheless, some ionic stabilizers 
(e.g., sulfate ester group: SDS or docusate sodium) are less 
prone to the logD alteration, thus enable them to better protect 
the nonspherical nanoparticles throughout various physiolog-
ical pH (e.g., nonspherical nanoparticles which are intended for 
oral administration route[139]).
3.4.5. Investigation, Elaboration, and Outlook of Residual 
Stabilizers
To extensively and systematically appraise the root causes of 
different residual stabilizer extent and affinity in nanoparticle 
system, we suggest to investigate the primary and secondary 
interfacial activity parameters of several commonly used stabi-
lizers and materials for particle formation. The former include 
SFE, interfacial tension, and WCA (Figure 5e). While, the latter 
consist of a) work of adhesion (also known as adhesion energy) 
between particle and stabilizer material in certain medium, i.e., 
water (WoA3), b) interfacial tension of core particle and stabi-
lizer material (IFT1.2), and c) the difference of WoA3 and IFT1.2 
(Figure S4, Supporting Information).
In the first priority, we propose to observe the difference of 
WoA3 and IFT1.2 to better represent the overall affinity between 
stabilizer and particle materials, which also complements the 
WoA3 and IFT1.2 concepts. It was already known that WoA3 only 
demonstrates the short-term affinity, while IFT1.2 describes 
the tension left in the formed bond (i.e., the bond’s potential 
to break), characterizing long-term affinity.[199] From the deduc-
tion of our results and others,[53,124,127,129,133,135,136,168,194] the 
nonwashability of PVA, sulfate esters, CTAB, and Triton X-100 
from various nanoparticles may strongly correlate to their pri-
mary and secondary interfacial activity parameters (Figure 5e 
and Figure S4, Supporting Information). Interfacial-activity-
based algorithms to determine the stabilizer nonwashability 
and suitability for particle formation are suggested (Figure S4c, 
Supporting Information).
To scrutinize the physicochemical properties that could be 
linked to the behavior and pattern of residual stabilizers on 
nanoparticle, we propose to investigate further some exam-
ples of small molecule stabilizers discussed previously here, 
by virtue of comparing their other, yet related experimental 
and computational physicochemical parameters (Table 3). 
Alongside the normal reported basic physicochemical para-
meters for (active) substances, we consider to introduce a 
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novel parameter, namely molecular polar surface area (PSA). 
PSA is the total area on molecule surface exerting merely 
polarized atoms (e.g., ultimately oxygen and nitrogen, also 
encompassing their bound hydrogens).[200] By this way, 
researchers can predict the partition degree of substances (in 
a diverse way as the conventional one, e.g., partition coeffi-
cient [logP and logD]), thereby estimate the molecular hydro-
phobicity,[201] conformation evolution,[202] as well as behavior 
towards various cell membranes recently.[203,204] PSA calcula-
tion gives results, which are proportionally comparable with 
the accessible surface area (ASA)[205] representing area of a 
molecule that is accessible to solvent (i.e., water). Addition-
ally, PSA is approximately up to two order magnitudes faster 
than ASA analysis.[200] The greater the PSA value (for instance 
≥140 Å2[203]), the more hydrophilic the substance, thus the 
poorer imbalance between hydrophilic and hydrophobic (or 
lipophilic) part of the substance, leading to its lower interac-
tion to the more amphiphilic matters (i.e., cell membrane). 
Therefore, it is not surprising that higher PSA displays poor 
membrane or cell permeation, e.g., through intestine[203,206] or 
blood–brain barrier (BBB).[206,207] In contrary, the lower PSA 
value (i.e., ≤60 Å2) was reported to have better equilibrium 
between hydrophilic and hydrophobic, hence the interplay 
between the substance and amphiphilic substrates occurred 
stronger.[203]
Through this inspiration and the comparison of cumula-
tive physicochemical properties of small molecule stabilizers 
(Table 3, Figure 5e and Figure S4, Supporting Information), it 
is getting clear that generally, nonwashable stabilizers should 
have a certain proportion of polar (hydrophilic) and disperse 
(hydrophobic or non-polar) (or so-called surface polarity, Xp) 
depending on the nature of particles, thus it can support their 
resistance on particles. These nonwashable characteristics 
(of small molecule stabilizers) are possessed by, for example 
sulfate esters, Triton X-100, and CTAB, demonstrating these 
characteristics: low surface tension (<40 mN m−1) at CMC, 
high logP (>2), high and virtually constant logD at various 
pHs (each >2), low intrinsic solubility (<–4.0 logS), and PSA 
< 120 Å2. Interestingly, hydrophilic–lipophilic balance (HLB) 
parameter, which is initially and frequently used as emulsion 
stability descriptor,[208] shows very poor correlation toward the 
residual stabilizers on nanoparticle system, which can be clas-
sified as suspension. Hence, HLB may be rather inappropriate 
to portray the stabilizer affinity on solids dispersed in liquid 
medium.
In addition, both interfacial activity parameters (Figure 5e) 
and other related physicochemical properties (Table 3) may 
also be appropriate to elucidate the inability reason of sev-
eral general stabilizers (e.g., polysorbate 80,[194] gelatin,[194] 
poly(vinylpyrrolidone) (PVP),[194] and PEG (4000)[209]) in 
assisting the formation of nanoparticles. It is strongly proven 
that these stabilizers were deviated widely from the suggested 
values (Figure 5e and Figure S4, Supporting Information 
and Table 3). Our databases may complement the old report 
of Albertsson,[210] still displaying no quantitative comparison 
between the macromolecular stabilizers. Nevertheless, his 
work is really influential to date and widely applied in phar-
maceutical area[106,211] to give insight of material (macromole-
cule) and nanoparticle hydrophobicity. In accordance with 
Albertsson’s report, dextran and its derivatives are the most 
hydrophilic polymers, while PVA and PEG have quite similar 
hydrophilicity (with PVA shows higher hydrophilicity). It can 
explain why dextran is totally not sufficient as stabilizer for 
hydrophobic aliphatic polyester nanoparticles development,[194] 
but fails to enlighten, why the more hydrophilic PVA can be 
a great stabilizer than PEG (4000[209]) for (aliphatic polyester) 
nanoparticle synthesis. In fact, to be bond with the hydro-
phobic aliphatic polyesters, the relatively more hydrophobic 
PEG variants (i.e., commonly methoxyPEG [(m)PEG] 2000,[212] 
3400,[213] till 5000[212,214]) should be covalently linked onto the 
aliphatic polyester backbone forming the block copolymer; 
where these block copolymers may form (micelle-like) nano-
particles in aqueous solution. Logically, if the Albertsson’s 
sequence is assumed to be fully valid, the PEG may exhibit 
spontaneous and higher adsorption onto hydrophobic ali-
phatic polyesters. The combination of interfacial activity para-
meters (Figure 5e) and other related physicochemical proper-
ties of stabilizers (Table 3) may clarify such PEG issue, i.e., 
PEG has too weak interfacial activity (SFE or surface tension 
≈55–65 mN m−1), too high solubility in water (positive logS) 
and high PSA (>≈1000 Å2), thus shows practically no presence 
at the interface due to its higher affinity to water molecules. In 
conclusion, the physicochemical properties generated by the 
computational method appear to be promising to equip our 
interfacial activity knowledge in comprehending its relation to 
the residual stabilizers.
Meanwhile, in case of big molecule (termed as macromole-
cule afterwards) stabilizers, hitherto it is still rather hard to con-
nect the residual macromolecule stabilizer on nanoparticle with 
their physicochemical properties due to the lack of appropriate 
physicochemical descriptor to be linked and great complexity-
plausibility of interactions. Also, even by means of computa-
tional simulation, it requires a lot of computation effort, time, 
and cost just for the basic physicochemical properties (e.g., 
Tg, WCA, etc[215]). Therefore, to date the limited experimental 
approach (i.e., interfacial activity parameters; Figure 5e) is the 
only source to understand this phenomenon. Nevertheless, we 
believe that the progress of macromolecule experimental and 
computational research will provide tools to unveil the holy 
grail of residual macromolecule stabilizer on nanoparticles. 
Recently, the novel trend to use computer-assisted drug formu-
lation design commenced.[216]
As an outlook, we envision that certain residual stabilizers 
can be vexed, both for manufacturing process and clinical trans-
lation of nonspherical nanoparticles. This is due to the fact that 
albeit implementation of clearly described and strictly stand-
ardized nanoparticle washing as shown in this report, in many 
cases we cannot neglect the existence of particular residual 
stabilizers. On the one hand, they can be an impressive com-
panion for particle shape stability, yet modulate other nanopar-
ticle physicochemical properties (e.g., Young’s modulus, surface 
roughness, Tg, porosity, residual moisture, and hydrophobicity). 
On the other hand, they may also be a potential threat for fur-
ther clinical application because almost all strongly retained sta-
bilizers on nanoparticles are renowned for their toxicity. Careful 
selection of currently available stabilizers and innovative mate-
rial development are demanded for the advancement of non-
spherical nanoparticles. Besides, the clear divulgence of used 
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stabilizer and washing process is very imperative. In the future, 
the nanoparticle research results should be more cautiously 
evaluated due to the inseparable influence of particle shape and 
surface chemistry.
3.5. Comparison to Nonspherical Silica (SiO2) Nanoparticles 
and Other Systems
Learning from excellent shape stability of SiO2 nanoparti-
cles (still having residual stabilizers) in physiologically rel-
evant condition, the further question may arise. How come if 
there are no residual stabilizers (or surfactants) at all during 
the manufacturing process? Could the nonspherical shape of 
nanoparticles dispersed in aqueous physiologically mimicking 
environment still persist? The answer is likely yes, but the 
Young’s modulus and liquefaction temperature (either Tg or Tm) 
of the material should be exceptionally high. For example, very 
hydrophobic single-walled carbon nanotube (SWCNT), having 
Tm of 4177 °C[217] and Young modulus of 1800 GPa making it 
as one of the stiffest material measured experimentally[218]), 
can be produced spontaneously without the presence of sta-
bilizer using arc-discharge evaporation.[219] This technique is 
the same as to produce other fullerenes, such as spherical C60 
(also, so-called Buckminsterfullerenes or buckyballs). Based on 
this, the member of fullerenes family may have similarity in 
terms of very great hydrophobicity. It has been reported that 
experimentally, spherical fullerenes are the most hydrophobic 
nanoparticles (regardless of their fabrication method) relative 
to gold and silver nanoparticles formulated with various sta-
bilizers.[220] It seems that their results concerning sequence 
of nanoparticle hydrophobicity may have a good correlation 
to the bulk material hydrophobicity (Figure 5e; case: gold vs 
unwrapped SWCNT). Therefore, we believe that the interfa-
cial activity database coupled by complete bulk-nanoparticle 
physicochemical properties may be an initial guidance (after 
internal structure status) to appraise the nonspherical particle 
shape stability in the dispersion medium. Since our interfacial 
activity database covers only the aqueous data, it is required 
more elaboration to provide similar database for nonspherical 
shape stability prediction in other dispersion medium (e.g., 
organic solvent, oil, etc.), which may be interesting for other 
research areas.[83,149]
Nevertheless, nothing is perfect in this world. Albeit the high 
plausibility of stable nonsphericity, fullerenes family inclines to 
flocculate in order to avoid their dispersion in solvents or vis-
cous polymer melts[221] due to their very hydrophobic nature. 
Stabilizers with highly strong interfacial activity and low-inter-
mediate surface polarity (about 44%, e.g., sulfate esters (spe-
cifically docusate sodium) and Triton X-100;[222] recall Figure 5e 
and Table 3) are generally required to disperse the fullerenes 
family in aqueous dispersion medium. It can be proven with 
our database (Figure 5e) and secondary interfacial activity para-
meter calculation, resulting the conclusion that both stabilizers 
are very likely nonwashable from SWCNT (e.g., Triton X-100 
with WoA3 25.51, IFT1.2 7.72, and the difference of WoA3-IFT1.2 
17.79 mN m−1). However, again the inextricability of particle 
shape and surface chemistry (as well as other physicochemical 
properties) is highly accentuated.
3.6. Lesson Learned from Nonspherical Particle Shape Stability
To make the inference of nonspherical particles shape stability, 
we should take into account all manufacturing aspects (including 
bulk and nanoparticle form) as well as their consequences to 
physicochemical properties. Otherwise, the fallacy is obtained. 
For example, if merely the hydrophobicity, molecular weight/vis-
cosity, and Tg properties in the bulk form are taken into account, it 
will be reasonable to put PLGA 50/50-COOH nanoparticles as the 
long-lasting nonspherical nanoparticles between the aliphatic pol-
yesters produced by nanoprecipitation. In fact, it had the poorest 
shape stability between the aliphatic polyesters prepared by 
nanoprecipitation. Relatively neglected properties (such as nano-
particle integrity, nanoparticle Young’s modulus, nanoparticle 
surface roughness, nanoparticle wet Tg, nanoparticle porosity, and 
residual stabilizers in nanoparticles) prove clearly that they should 
also be carefully and simultaneously assessed. Another instance 
is O-CMCHS. Despite its great bulk hydrophilicity (Figure 5e) 
and Tg (140–150 °C),[81] the nonsphericity of O-CMCHS nano-
particles is the worst among other materials studied here. Lack of 
nanoparticle integrity is responsible for this reason.
In contrary, we cannot conclude the nonspherical shape 
stability based on only the (partial) nanoparticle proper-
ties. For instance, gelatin nanoparticles were the smoothest 
surface (Rrms = 3.2 nm) nanoparticles, which usually may 
lead to the lesser hydrophobicity degree.[37] However, non-
spherical gelatin nanoparticles were ones of the least stable 
nanoparticles in terms of nonsphericity. This could not be 
separated from the poor nanoparticle integrity (demonstrated 
by swelling), relatively high porosity (1.57 m2 g−1), soft (nano-
particle Young’s modulus of 0.7 GPa), and great hydropho-
bicity (both in bulk and nanoparticle forms; Figure 5d,e). 
Further example, SiO2 nanoparticles have the highest 
porosity (generally ranging from tens to hundreds m2 g−1), 
that may be interpreted one of the risk of nonspherical shape 
instability. Nonetheless, because of very low hydrophobicity and 
great mechanical properties (high Young’s modulus 73 GPa, 
acceptable surface roughness ≈2.5–10 nm, and Tm 1600 °C), it 
turns out that SiO2 nanoparticles are ones of the most stable 
nanoparticles in terms of nonsphericity.
To sum up, in relation to the nonspherical particle shape sta-
bility, negative factors (high hydrophobicity, surface roughness, 
and porosity) of nanoparticles are counterbalanced by positive 
factors (existence of nonspherical structure, high stiffness, 
and liquefaction temperature). According to our experimental 
results and some available reports, the detail considerations of 
manufacturing aspects toward nonspherical shape stability and 
their potential biological relations are summarized in Table 4.
4. Conclusions
Particle shape is one of the most critical parameters in drug 
delivery. This momentousness should be verified further and 
heedfully for reliable in vitro and in vivo experiments. Our 
report strongly suggests that shape alteration tendencies of 
nonspherical particles (having no specific internal structure) 
to spherical particles may occur in favor of thermodynamic 
(due to trigger of material–water interfacial tension), and the 
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Table 4. Contrast and deliberation of manufacturing aspects toward (nonspherical) particle’s physicochemical properties and their potential 
biological relations.
Advantages Manufacturing aspects Disadvantages
•   ↑ Aspect ratio → ↓ probability for phagocytosis by macrophages[8,19] 
→ ↑ circulation time[4]
•   ↑ Surface area → ↑ “loading” of active pharmaceutical ingredients 
(APIs) (in case of APIs should be tethered onto surface[9,22,64,267])
•   ↑ Polymer orientation and crystallinity* (*in case of semicrystalline 
ones) → ↑ rigidity and liquefaction temperatures (Tg and Tm)  
→ ↑ nonsphericity stability
•   ↑ Variance of particle’s radius of curvature (Rc(t)) → ↑ choices for 
other unique related phenomenas (e.g., substance adsorption-
stability, liquefaction temperatures [Tg and Tm], etc.)
•   Bestow relatively same volume as the starting spherical* particles 
for better in vitro and in vivo study comparison (*as long as the 
integrity of particles is sufficient)
Stretching
(e.g., using film-stretching 
method)
•   ↑ Surface area → ↑ possibility of APIs burst release
•   ↓ Density and amount* of stabilizer (*in certain case, e.g.,  
P407 extracted by PVA[106])
•   ↑ Surface roughness
•   As above consequences: generally ↑ contact area of pressure  
and hydrophobicity → ↓ non-sphericity stability
•   ↑ Variance of particle’s (Rc(t)) → ↑ presence, abundance  
& degree of highly curved surface areas → ↓ non-sphericity stability; 
in fact, highly curved areas / smaller (Rc(t))s are already proven in 
vitro[268] and in vivo[118] to generally impact  
the following properties of adsorbed (blood) proteins:
◦  ↓ Total amount of adsorbed proteins
◦  Modulate cumulative adsorbed proteins’ surface hydrophobicity 
(Φf) depending on particles’ surface hydrophobicity:[269]
▪  ↓ (Rc(t)) on ↓ hydrophobic particles → ↑Φf[268]
▪  ↓ (Rc(t)) on ↑ hydrophobic particles → ↓Φf[118] → however, 
evidently the ↓Φf and quite ↓ total amount of adsorbed 
proteins can not avoid the strong confinement effect on ↓ 
liquefaction temperatures (Tg and Tm) that are caused by too 
↓Rc(t) → drastically ↓ nonsphericity stability[118]
◦  ↓ Cumulative negative charge of adsorbed proteins, leading  
to the ↓ zeta potential of particles
•   ↑ Dissolution rate-solubility of APIs and permeability (Nano-)size •   ↑ Polymer degradation
•   ↓ Surface-free energy and ↑ interfacial tension  
(∼↑ hydrophobicity[211]) → ↑ pressure / force against  
particles → ↓ nonsphericity stability
•   ↑ Dissolution rate solubility and loading of APIs Porosity •   ↑ Polymer degradation
•   ↑ Inclination of residual moisture → ↓ nonsphericity stability
•   ↑ Permeability and cellular uptake Hydrophobicity •   ↓ Nonsphericity stability
•   ↑ Total amount of adsorbed (blood) proteins & ↑ opsonization  
(especially for ↑Φf [blood] proteins[268,269])
•   ↑ Viscosity, Tg, and rigidity → ↑ Non-sphericity stability* (*in case  
of non-washable stabilizer involvement during particle fabrication; 
e.g., emulsion solvent extraction)[26]
•   ↑ Degradation time
(“High”) molecular weight  
and viscosity of polymer
•   ↑ Particles size & size distribution, porosity* (*in case of nonwash-
able stabilizer involvement) and surface area
•   ↓ Yield of fabricated nanoparticles (in case  
of nanoprecipitation)
•   ↓ elasticity and hydrophilicity
•   ↑ Interfacial tension
•   ↓ Hydrophobicity (charged condition; pH is far from pKa) → ↑ 
nonsphericity stability
Functional group  
modification of polymer  
(viz. carboxyl-ended)
•   ↑ Hydrolysis → ↓ degradation time (i.e., aliphatic polyesters)
•   ↓ Permeability → ↓ cellular uptake (by healthy cells)
•   ↑ Hydrophobicity (less-charged condition; pH is closer to pKa);[26] 
example: due to relatively more acidic intracellular compartment 
(Table 3) of healthy cells or extracellular compartment of cancer 
cells,[270] -COOH (pKa 3.85) is ↑ protonated → ↓ nonsphericity 
stability[26]
•   ↓ Hydrophobicity by ↓ interfacial tension → ↓ adsorbability of 
(blood) proteins
•   ↑ Mechanical properties (in some variants, e.g., PVA enhancing 
Young’s modulus & Tg)
•   ↑ Nonsphericity stability (by ↑ residual stabilizers; i.e., particular 
PVA, which may have biological disadvantages (as described  
on the right))
Stabilizers
(e.g., PVA, poloxamer, TPGS, 
SDS, PEGylation, etc.)
(If too much and highly attached residual stabilizers onto particles)
•   ↑ Specific surface area (SSA; e.g., relatively more substantial SSA 
↑ by PEG)[269,271] &/ ↓ liquefaction temperature (e.g., Tg by PEG[272] 
Triton X-100,[124] Poloxamers,[273] etc.) → ↑ burst release[124,269,271] 
&/ ↓ nonsphericity stability
•   ↓ Hydrophobicity → ↓ permeability & cellular uptake
•   ↑ Formation of specific antibodies (e.g., PEG)[274] → ↑ clearance  
of drug vehicles[275]
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rate at which this change occurred do not only depend on the 
bulk material properties and storage temperature, but also 
importantly on the physicochemical properties of the resulted 
nanoparticles. Besides, this rate of shape transformation can 
be simply tuned with the presence and extent of residual stabi-
lizers. The evidence is displayed by decrease of aspect ratio (AR) 
and hydrodynamic size as well as PDI. In case of biodegrad-
able polymeric nanoparticles, aliphatic polyester nanoparticles 
prepared by emulsion solvent extraction using certain PVA 
was remarkably superior in terms of nonspherical nanopar-
ticle shape stability compared to nanoparticles fabricated by 
other stabilizers, purely nanoprecipitation method, different 
materials, and manufacturing techniques. It appears that the 
residual stabilizers can be a great companion for nanoparticles 
in maintaining their nonsphericity, if they are considered as a 
nontoxic, biodegradable, and biocompatible material.
Adv. Healthcare Mater. 2019, 8, 1900352
Advantages Manufacturing aspects Disadvantages
•   Common & safe administration media for drug delivery system
•   ↑ Nonsphericity stability by formation of more stable 
polymorph[163,276]
Water
(including humidity)
•   ↓ Liquefaction temperatures (Tg[40] and Tm[277]) → ↓ nonsphericity 
stability by considerable interfacial tension discrepancy, specifically 
at less-charged condition (i.e., pH is closer to pKa [if any] of such 
particle material[26] in case of shape-memory polymeric particles) & 
↓ particle’s (Rc(t)) (including also metallic particles[117–119])
(Note: In agreement with compendia from several authorities,[278–280] 
the pH of highly purified water (HPW) should not necessarily be 7.0, 
but it can be between 5.0 and 7.0, as the used HPW here, i.e., pH 
5.5-5.8 (∼endosomal pH[265]) and elsewhere.[150] Thus, water aspect 
should be assessed carefully and on a case-by-case basis).
•   ↓ Residual stabilizers until minimum depending on the nature of 
stabilizers (reportedly, purification efficiency of certain centrifuga-
tion ∼Cross-flow filtration [CFF][127] aka tangential-flow filtration 
[TFF][281] aka ultrafiltration[282] ≥ gel permation chromatography 
[GPC][105] aka gel filtration chromatography [GFC] aka size-exclusion 
chromatography [SEC], especially for easily washable stabilizers, 
e.g., poloxamer groups[105]) → ↓ toxicity, but this may also bring 
disadvantages (as described on the right)
Purification (if too “clean”, particularly for easily washable stabilizers)
•   ↓ Non sphericity stability & ↑ particle aggregation[196] chiefly in case 
of hydrophobic, porous and/or amorphous (no specific internal 
structure in) particles
   (Only by particular compendial methods[278,280,283] [e.g., sterile 
filtration using membranes ≤ 0.22 µm or presterilization+aseptic 
processing] which still virtually maintain non-sphericity stability)
•   ↑ Sterility
Sterilization (For sterile filtration)
•   Practically impossible to be applied to spherical particle Ø 
> 0.22 µm or nonspherical particle owing minor axes > 0.22 µm
•   May ↓ particle yield depending on the properties of particles (e.g., 
size, hydrophobicity, charge, etc.)
(Many cases of compendial sterilization methods[278–280,283,284] e.g., 
a) steam [≥ 121 °C for 15 min], b) dry-heat sterilization [≥ 160 °C for 
≥2 h], c) ionizing radiations [normally 25 kGy or 2.5 Mrad], either 
beta- or gamma-irradiation, and d) gas [e.g., ethylene oxide with 
residual limit ≤1 ppm[285]])
•   Generally ↑ surface roughness[31] and residual moisture aka water 
content[286]
•   ↓ Young’s modulus (in case of amorphous materials)[287]
•   Frequently ↓ molecular weights of polymers (especially for blank 
particles) → ↓ liquefaction temperatures (Tg and Tm[288]) & ↓ SSA → ↑ 
aggregation & ↑ possibility of APIs burst release[289,290] 
•   As above consequences: ↓ Nonsphericity stability
Nevertheless, sterilization aspect should still be assessed carefully 
and on a case-by-case basis
•   ↑ Stability (e.g., cryoprotectants; if lyophilization is needed) Other additional substances 
(e.g., APIs, excipients, etc.)
•   ↓ Nonspherical stability (i.e., counter-ion,[26] substances causing 
preparation’s pH ∼pKa of [e.g., polymeric] vehicles,[26] loaded[158,291]/
adsorbed hydrophobic substances[26] including proteins,[291] 
substances ↓ liquefaction temperatures of whole particles, such as 
gentamicin → also ↑ burst release,[290] [if applicable] residual oil 
during particle fabrication, etc.)
•   ↑ Nonsphericity stability (e.g., PBLG[142]) (Stable, ordered and 
nonspherical)
Internal structure/crystal 
system/crystallographic form
•   ↓ Drug loading (e.g., stable β-polymorph of crystalline lipids,  
such as triglycerides[115,160,161]
•   ↑ Toxicity
Table 4. Continued.
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